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ABSTRACT
This thesis examines the temporal expression of the Insulin-like growth
factor type 1 receptor gene (IGF-1R) in the evolution of human colo-rectal cancer.
The IGF-IR is a highly conserved transmembrane receptor tyrosine kinase that is
expressed at high levels in embryonic stem cells and in many cancer phenotypes.
However, the IGF-IR is expressed at lower levels in some advanced cancers. The
reasons for this and the timing of these changes in expression during neoplasia are
not understood. Herein these studies examine IGF-IR expression in human colo¬
rectal neoplasia by means of Northern blotting and Immunohistochemistry
validated by tissue and reagent controls and by Western blotting. The studies show
that in the normal human colon, adult stem cells in the basal crypt region express
high IGF-IR levels which decrease to low levels when these cells migrate to and
differentiate in the mid and upper crypt regions. In the aberrant crypt focus, the
transformed cells express high IGF-IR levels throughout the crypt axis despite
showing varying degrees of differentiation. This pattern of high IGF-IR expression
occurring de novo in colo-rectal neoplasia continues with neoplastic progression in
adenomatous polyps and cancers. However, reduced IGF-IR expression is seen in
some advanced cancer phenotypes - in epithelial-type cancer cells that show a fully
polarised morphology in areas with epithelial-mesenchymal type transformation
(EMT) and in invasive mesenchymal-type cancer cells that show a loss of cell-
basement membrane or cell-cell adhesion after EMT. These morphological changes
account for the low levels of IGF-IR expression seen in advanced invasive cancers in
the current studies. These studies provide basic insights into how IGF-IR expression
in normal cellular development is disrupted at tumour initiation and progression
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Fifty years ago the first of the modern day oncologists Rupert Willis defined
cancer as "an abnormal mass of tissue, the growth of which exceeds and is uncoordinated
with that of normal tissues" (Willis, R.A.,1952 ). The last thirty years have seen cancer
researchers define the disease in terms of gene mutations. The last decade however has
seen cancer defined increasingly in terms of the cell signalling network
The complexity of cell signalling network is slowly being decoded (Hanahan,
2000)(Figure 1.1). This is a network of interconnected and highly redundant signalling
pathways that integrate the cell's extracellular milieu with intracellular function including
gene transcription. Put simply, extracellular ligands bind to their cognate cell membrane
receptors to activate cytosolic signalling cascades that transduce to the nucleus where
they control gene transcription. The resulting changes in gene transcription, although
poorly understood, control normal cell behaviours including cell proliferation, cell
survival, cell differentiation and cell-cell / cell-substrate adhesion. Components of the
signalling network are targeted in the majority of cancers (reviewed Hanahan, 2000;
Nurse, 2000). Here, during tumour initiation and progression, changes in gene expression
or gene mutations occur in these signalling components to change normal cell growth to
the abnormal "uncoordinated growth" of the cancer cell as described by Willis.
This thesis examines one component of the cell signalling network in relation to
the "uncoordinated growth" of neoplasia. It examines the expression of the insulin-like
growth factor type 1 receptor (IGF-1R) in colo-rectal neoplasia. The IGF-1R is a highly
conserved receptor tyrosine kinase which has a central role in the cell's signalling
network in the control of cell proliferation, cell survival, cell differentiation and cell-cell /
cell-substrate adhesion (summarised in Figure 1.1; reviewed Baserga, 1999, 2000;
Valentininis, 2001; Mauro & Surmacz, 2004; LeRoith, 2000; O'Connor, 2000, 2003). The
IGF-1R is also at one of the crossroads of the cancer cell's signalling network and many
tumour mutations target components of this signalling network. There is extensive
clinical and experimental data to indicate an important role for the IGF-1R in neoplasia of
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the breast (Surmacz, 2000), prostate (Djavan, 2001), colon (Giovannucci, 2001), lung
(Wu, 2000), pancreas (Korc 1998), liver (Scharf, 2001), ovary (Druckmann, 2002),
bladder (Hursting, 2001) and brain (Zumkeller, 1999). Most cancers, including those of
the colo-rectum, over express the IGF-1R (Macaulay, V.M., 1992), (Zhang, L., 1997) but
there is now evidence to show that the IGF-1R is not as highly expressed in some
advanced cancers of the colo-rectum (Nakamura, M., 2004), breast (Schnarr, B.,
2000)(Pennisi PA, 2002) and prostate (Hellawell, G., 2002). The reasons for this and the
timing of these changes in IGF-1R expression during neoplasia are unknown. This thesis
examines these changes in IGF-1R expression during neoplasia, using the colo-rectal
polyp-cancer sequence as a model of tumour initiation and progression.
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Figure 1.1 The Cell Signalling Network and the IGF-1R
The membrane / cytosolic / nucleus signalling network that integrates the extracellular
environment with the nucleus and gene expression. Growth factors (including IGF-1), the
extracellular matrix and other components of basement mebrane and cell membrane bind
their respective receptors - growth factor receptor tyrosine kinases (including the 1GF-
1R), E-cadherin, integrins and frizzled. This activates a complex series of interconnected
signalling cascades - ras / MAPK, PI3K, APC / (3-catenin, JAK /STAT, SMAD. These
cascades in turn translocate to the cell nucleus where they control gene transcription to
determine cell behaviours such as cell proliferation, cell differentiation, cell adhesion and
cell survival.
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(Reproduced from Douglas Hanahan. The Hallmarks of Cancer, Cell 2000. 100:57-70)
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1.2. A human cancer model: colo-rectal crypt-cancer evolution
Colo-rectal cancer is the third commonest cause of cancer mortality in the western
world. In the UK, the incidence of colo-rectal cancer is 35,000 newly diagnosed cases per
year whereas in the western world the estimated incidence is at least half a million cases
per year.
The classification of the colo-rectal cancer has evolved over the last 70 years from
Dukes' pathological description of the disease (Dukes, 1932,1958); to Muto's description
of its pathogenesis in the ACF-polyp-cancer sequence (Muto, 1975); to Vogelstein's
description of its germline and acquired genetic mutations (Fearon and Vogelstein, 1990).
We can place these models in the context of the cell's signalling networks. The colo¬
rectal sequence of normal to aberrant to adenomatous and then cancerous crypt provides
an ideal model system with which to analyse the expression profile of the IGF-1R during
the evolution of a human cancer.
The normal colonic crypt
The normal colonic mucosa is arranged in single layers of infolded columnar
epithelium to form glands or crypts which are monoclonal in origin (Endo, Y., 1995).
Crypts arise from a population of stem cells located in the lowermost 16 or so cells in the
lower third of the crypt (Potten, C.S., 1992). These proliferative cells have an
undifferentiated and partially polarised morphology with nuclei that are aligned a short
distance "off" the basal aspect of the cell membranes. The basal stem cells generate a
population of proliferating transit amplifying cells that occupy the middle third of the
crypt. These transit amplifying cells remain pluripotent and capable of proliferation for
some six or seven cell layers (Potten, C.S., 1992). The cells are partially polarised and
sometimes partially differentiated. Thereafter, in the upper third of the crypt the cells
fully differentiate to generate mature enterocytes, neuroendocrine cells, Paneth cells and
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mucous-secreting goblet cells (Potten, C.S., 1990). These differentiated cells are fully
polarised with nuclei that are aligned "on" the basal aspect of the cell membranes. On the
luminal surface, these differentiated cells undergo programmed cell death and are shed
into the lumen.
The volume of the crypt is determined by: cell cycling rates in the stem and transit
amplifying regions; differentiation and programmed cell death rates in the terminal
differentiated compartment; and rarely, by apoptosis which can occur in the transit and
differentiated compartments. Apoptosis does not appear to occur in the basal stem cells of
the colon. This and the pluripotency of transit cells are thought to be important
contributory factors in the evolution of colon cancer (Potten, C.S., 1992). This may also
explain the reduction in apoptosis seen in colorectal polyps. The stem cell can cycle at
between 15 to 22 hours whilst cell migration to the upper differentiated compartment
takes about 6 days. In contrast, the latent period between the initiation of an ACF and the
emergence of a cancer can be up to 10 to 15 years. Thus initiated tumoural cells must
have a life span commensurate with this and be able to avoid migration, differentiation,
programmed cell death and shedding from within the crypt. Basal stem cells are therefore
the likeliest candidate tumoural progenitors which satisfy these requirements.
The three basic phenotypes in the enterocyte lineage of the normal colonic crypt
differ in the expression profiles of many genes. For example, the cell survival gene bcl-2
is expressed in the basal stem compartment (Merritt, AJ., 1995), (Sinicrope, F.A., 1995);
some growth response genes such as myc, fos, cyclin D1 and EGFR are expressed in the
stem and transit compartments (Chin, L., 1995), (Stopera, S.A., 1992), (Chailler, P. &
Menard, D., 1998); whilst some anti-proliferative or differentiative genes such as APC
and TGF|3RII are expressed in the upper differentiated compartment (Smith, K.J., 1993).
Other genes such as E-cadherin appear to be constitutively expressed throughout the
length of the crypt (Sellin, 2001). We can therefore infer to a limited degree the
characteristics of a gene by its expression profile within the normal colonic crypt.
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The aberrant crypt focus : tumour initiation
There is observational evidence that aberrant crypts are the precursors to
adenomatous polyps which in turn are the precursors to the majority of colorectal
cancers. For example, ACFs were first observed in animals treated with colon
carcinogens (Deschner, E.E., 1974) (Tudek, G., 1989) and in humans with colon cancer
(Shansuddin, A.K.M., 1981). Also, ACFs and polyps both have the same anatomical and
epidemiological distribution as cancers (Ronucci, L., 1991), (Ronucci, L., 1998), (Muto,
T., 1975) and carcinoma-in-situ has been seen to arise in ACFs and polyps
(Konstantakos, A.K., 1996).
Histologically the aberrant crypt focus exhibits a lack of differentiation in
comparison to the normal colonic crypt. Additionally, cell crowding occurs and there
may be an increase in nuclear size with heterogeneity and hyperchromasia, features that
constitute a dysplastic ACF. The cells are partially polarised with nuclei that are aligned
"off' the basal membrane.
The earliest detectable cell kinetic abnormalities at this stage consist of an
increased proliferation in the basal and transit amplifying compartments (Lipkin, M.,
1988) and a reduction in programmed cell death in the upper differentiated compartment
of the crypt (Bedi, A., 1995). The zone of proliferation expands to occupy the entire
aberrant crypt (Ronucci, L., 1993), (Otori, K., 1995), (Shpitz, B., 1997). Thymidine
labelling studies have shown continued DNA synthesis suggesting that the mechanisms
which normally shut off DNA synthesis in the upper two-thirds of the crypt are non
functional at this early stage.
Tumour initiation as represented by the ACF exhibits high expression levels of
bcl-2 and c-fos (Stopera, S.A., 1992), (Hague, A., 1994). Some mutations are also
documented with increased frequency. APC mutations have been documented in up to
4.6% (Smith, A.J., 1994), (Otori, K., 1998) and K-ras mutations in 13% to 50% of ACFs
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(Takayama, T., 1998), (Pretlow, T.P., 1993). p53 mutation or expressive changes in p53
have not been found in ACFs (Losi, L., 1996) but decreased expression of p21, a target
of p53, has been documented in some dysplastic ACFs (Polyak, K., 1996). This pattern of
unchecked expressive change in cell cycle and cell survival genes along with activating
mutations in their component pathways continues throughout neoplastic progression.
Adenomas: tumour progression
Continued proliferation in the ACF results in crypt fission, expansion and
infolding of epithelial cells to give the characteristic glandular polyp seen in tubular
adenomas. Histologically, the cells are tall, thin, crowded and relatively lacking in
differentiation. They can have pseudostratified nuclei at different levels giving a "picket
fence" appearance. However, the cells retain a partially polarised morphology with the
lowermost nuclei aligned "off" the basal membrane. There is a spectrum of cytologic
atypia. Some cells can progress to dysplasia and anaplasia but most will remain in orderly
palisades. Cell growth control is not entirely abrogated at this stage but whilst some
adenomas may spontaneously regress, the majority are thought to inexorably progress,
undergoing clonal expansion and further mutations (Bersentes, K., 1997). Proliferation
and overgrowth of the underlying and probably normal mesenchyme is also an important
component of polyp development. In its advanced form it can result in glandular
projections characteristic of villous adenomas. Continued unchecked epithelial cell
proliferation in these larger adenomatous and villous polyps will commonly result in
progression to the features of cytologic atypia and dysplasia. Here cells become more
crowded with larger, hyperchromatic nuclei exhibiting pleomorphism and lesser degrees
of polarisation. Tumour progression in adenomas has been represented as involving gene
expression changes - including the increased expression of cyclin Dl, c-myc and EGFR;
and the reduced expression of E-cadherin and TGF(3RII (Zhang, T., 1997),(Melhem,
M.F.,1992) - arising in concert with multiple gene mutations that include APC, K-ras,




At the next stage, cells can pile up upon one another, losing their palisaded
architecture but remaining confined to within their basement membrane. This constitutes
carcinoma in situ and correlates most closely with aneuploidy and p53 mutations which
occur in 50% of CIS (Rodrigues, N.R., 1990).
Cancer
At this stage, the cancer cells exhibit the capacity to invade through the basement
membrane. To do so, the cells undergo 2 morphological changes :
1. they loose their differentiated epithelial-type pallisaded alignment and undergo
transformation to an undifferentiated mesenchymal-type morphology (EMT - see
below);
2. they exhibit motile or invasive behaviour with the loss of cell-cell and cell-
basement membrane adhesion and invasion through the basement membrane.
Most of the cells in the cancer specimen however will commonly exhibit a more ordered
appearance and maintain a well, moderately or poorly differentiated morphology with the
cancer cells maintaining some form of cell-cell or cell-basement membrane contact and
confinement. The cells exhibit a high incidence of aneuploidy and p53 mutation at this
stage.
Epithelial mesenchymal transformation (EMT)
EMT occurs during the critical stages of embryonic development. An analogous
process occurs in the advanced stages of cancer development where cancer cells change
from an epithelial to a mesenchymal-type morphology (Reviewed Thiery, 2002). Cancer
cells undergoing EMT loose their polarised and palisaded epithelial type appearance and
adopt an unpolarised and undifferentiated mesenchymal type appearance. Changes in
gene expression such as reduced expression of the epithelial marker E-cadherin occur
during EMT in cancer specimens (Frixen, 1991). In vitro, EMT (and in particular
"scattering") is dependent on growth factors such as HGF, IGF-1 and -2, FGFs, EGF and
TGF-|3 which can reduce the expression of E-cadherin (Thiery, 2002). The mechanisms
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of this are not clear. IGF-1R for example forms a complex with E-cadherin and (3-catenin
which results in the lysosomal degradation of E-cadherin and the translocation of (3-
catenin to the nucleus where together with Tcf it induces transcription of genes such as
Myc (Morali, 2001). However, the exact mechanism(s) of change in E-cadherin
transcription are unknown. Similarly, it is not known if the growth factor receptors
themselves (such as the IGF-1R) undergo expressive change during EMT.
As noted above, following EMT, the mesenchymal type cells are not necessarily
invasive and can still maintain their cell-cell and cell-basement membrane contacts. That
is, poorly differentiated mesenchymal type cancer cells can maintain cell-cell and cell-
basement membrane contacts in a manner similar to well and moderately differentiated
epithelial type cancer cells. However, because the process of EMT cannot be followed
temporally and accurately in cancer specimens, the exact sequence of events during EMT
and invasion is difficult to discern. There is commonly considerable morphological
overlap between EMT and frankly invasive cells. These processes will be examined in
this thesis.
Invasive cancer
Here cancer cells show frank invasion through the basement membrane or blood
vessel endothelium or lymphatics. The cells have lost their cell-cell and cell-basement
membrane adhesion and show a motile mesenchymal morphology with lamellipodia.
They continue to show a reduction in E-cadherin expression and additionally express
proteases such as kallikreins (Borongo, 2004).
Metastasis and mesenchymal epithelial transformation (MET)
Once cancer cells have moved via direct invasion, the bloodstream or lymphatics
to a distant site or organ, they can form a secondary carcinoma and undergo a reverse
process of mesenchymal-epithelial transition (MET). Again, the temporal sequence
involved in this process or the changes in gene expression associated with this are not
understood.
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Figure 1.2 Crypt -*■ cancer evolution : normal epithelium -* ACF / adenoma
CIS - epithelial cancer -* mesenchymal cancer -» invasion -* metastasis
Normal epithelial cells have a palisaded appearance with cell-cell contact and cell-
basement membrane contact. They have a partially or fully polarised morphology
(depending on their mitotic state and differentiation) with nuclei aligned either off or on
the basal aspect of their membranes respectively.
ACF and adenomatous cells also have a palisaded appearance with cell-cell and cell-
basement membrane contact. However their nuclei are partially polarised and are
frequently at differing levels to give a "picket fence" appearance.
Cancer cells show varying degrees of differentiation but frequently have "heaped up"
highly mitotic cells separated from the basement membrane. Although most of the cells
show some form of cell-cell or cell-basement membrane contact, foci exhibit epithelial-
mesenchymal transformation (EMT) with loss of these contacts or frank invasion through
the basement membrane.






(Reproduced from Jean Paul Thiery. Epithelial-Mesenchymal transitions in tumour progression. Nature Reviews Cancer. 2002. 2:442-
454.)
20
1.3. Cell signalling and the IGF-1R
From the foregoing discussion it will be clear that the histopathologist's
description of "uncoordinated growth" in the colo-rectal crypt-cancer model might be
described in terms of abnormalities in the cell signalling network necessary to cause
abnormal cell proliferation, cell differentiation, cell adhesion and cell survival. These are
in fact purely arbitrary distinctions as even with our current limited understanding we can
see that cell signalling pathways and cell behaviours frequently interconnect and overlap.
We will examine next some of these main signalling pathways with particular reference
to the IGF-1R and cell behaviours.
Growth factor receptor signalling and the cell cycle
Growth factor receptor signal transduction pathways control the cell cycle and are
primary targets for cancer mutations. Programmed differentiation also takes its cues from
these pathways and the cell cycle. Of the purported 32,000 genes sequenced in the human
genome project, approximately 20% are thought to encode components of these growth
factor signal transduction pathways (Blume-Jensen, P., 2001). Of the one hundred and
thirty or so oncogene and tumour suppressor mutations identified to date in human
cancers, the majority are seen to target these growth factor signalling pathways.
In the normal cell, the control of these pathways starts at the level of cell
membrane with the binding of a growth factor to its respective receptor tyrosine kinase
(RTK). Some 58 RTK subtypes have been identified and of these some 31 have been
identified as being directly involved in cancers through mutational or expressive changes
(Blume-Jensen, P., 2001). Some RTKs have specific cell cycle functions. For example,
the binding of a "competence" growth factor (e.g. epidermal growth factor - EGF;
platelet-derived growth factor - PDGF; or fibroblastic growth factor - FGF) to its cognate
RTK is known to advance a quiescent GO cell into the G1 phase of the cell cycle (Rubin
R., 1995). Thereafter, a "progression growth factor" (e.g. insulin-like growth factor type
1 - IGF-1) is required to advance the cell through the restriction point into the synthetic
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phase of the cell cycle (see figure 1.3). Although this process is very incompletely
understood, it does mean that in practical terms a non-transformed cell is reliant upon at
least two growth factors (e.g. PDGF and IGF-1) for optimal cell growth. In contrast,
cancer cells display a greatly reduced reliance upon these factors principally, it has been
thought, by acquiring a combination of mutations and expressive changes in the pathways
described here (see figures 1.1 and 1.4). However, the breadth and scope of those
combinations required for cell cycle advancement in individual cancer phenotypes are
poorly understood at present.
Binding of a growth factor to its cognate RTK results in a conformational change
in the RTK's cytoplasmic domains to recruit a diverse array of signalling substrates
(including Src, GAP, Shp2, p85/P13K, Grb2, PLCg, Crk, Stat, IRS-1 and 14.3.3)(see
figure 1.4). Although some substrates recruit to specific receptors (e.g. IRS-1 to IGF-1R;
She to EGFR and IGF-1R; and pl20 to EGFR, PDGFR, VEGFR and NGFR) there is
more commonly a considerable overlap between RTKs and their signalling molecules.
These signalling molecules recruit second messengers that in turn are integrated into a
complex hierarchy of signalling cascades. These can be summarised in terms of six
principal pathways which act to control the cell cycle and influence differentiation and
which are targeted in the majority of cancers (see figures 1.1 and 1.4):
1. The ras/raf-l/MAPK pathway - This is activated by EGFR, IGF-1R, PDGFR and Met.
This signalling cascade translocates to the cell nucleus where the highly conserved
MAPK module targets the transcription of growth response genes such as myc, fos and
jun and cyclin Dl, necessary for the control of the cell cycle. Ras mutations are amongst
the commonest mutations in human cancers whilst MAPK is over expressed in the
majority of human tumours including late-stage colorectal tumours (Hoshino, R.,1999).
2. The PI3K/Akt pathway - This is activated by PDGFR, IGF-1R, EGFR, Met, FGFR and
E-cadherin. This pathway targets BAD and Bcl-2 (anti-apoptotic regulators), p70 (a
ribosomal kinase necessary for translation and the regulation of cyclinD3 in the cell cycle
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apparatus) and GSK3 (which phospho-inhibits APC) and can mediate cell cycle and anti-
apoptotic controls (Blume-Jensen, P., 2001). The pathway is targeted in many advanced
cancers including late-stage colorectal cancers, either through expressive changes or
through mutation of Akt-regulating PTEN (Cantley, L.C., 1999).
3. The Wnt/APC/ (3-catenin/Tcf pathway - This pathway modulates the Tcf/LEF family of
HMG box transcription factors involved in cell differentiation and components of this
pathway are well recognised mutational targets in colon cancer (Hunter, T., 1997). |3-
catenin also putatively forms a tripartite complex with the IGF-1R and E-cadherin and
regulates myc and cyclin D1 expression (Tetsu, O., 1999).
4. The cvclin Dl/cdk4/Rb pathway - The above 3 pathways trans activate the cyclins,
principally cyclin Dl, and thus initiate G1S cell cycle progression through a well defined
path (see figures 1.1 and 1.3). One element of the cyclin Dl/cdk4/Rb pathway is targeted
in the majority of cancers (Sherr, C.J., 1996).
5. The Cadherin pathway - These cell surface receptors modulate cell-matrix adhesion by
signalling via the src-family of RTKs (such as IGF-1R) to activate Wnt signalling.
Function of this pathway is lost in the majority of epithelial cancers (Christofori, G.,
1999). E-cadherin expression is also down regulated during the late polyp-cancer
sequence (Ilyas, M.,1997) and in EMT as previously described.
6. The p53 and TGF|3RII/SMAD pathways - As important as the growth factor- and
anchorage-dependent assembly of cyclin/CDK complexes at the cell cycle restriction
point is their TGFbRII- and p53-dependent disassembly at the cell cycle G1S checkpoint
(figure 1.3). p53 trans activates or inhibits a vast array of cell cycle and apoptotic genes
principal amongst which are the CDK inhibitor p21CIPl/WAF; the growth factor
receptors IGF-1R and EGFR; and the pro-apoptotic bcl-2 antagonist Bax (Levine, A.J.,
1997). P53 and TGFbRII/SMAD undergo mutational or expressive changes in many late
stage colo-rectal tumours (Rodrigues, N.R., 1990),(Zhang, T., 1997).
23











The cell cycle : mitogenic growth factors (via pathways 1 to 5 above) advance the cell cycle
through G0G1 and the G1S restriction point (represented by arrows in green) whilst
TGF(3RII and p53 (via pathway 6 above) inhibit the cell cycle at the checkpoint
( represented by an X in red).
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Figure 1.4 RTK / IGF-1R signalling, cell cycle genes and cancer : Genes undergoing
mostly expressive change in cancer are in green whilst the commoner oncogenes and
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1.4. Growth factor receptor signalling and colon carcinogenesis
Colorectal cancer studies over the last decade have provided some insights as to
how extensive mutational and expressive changes are in these growth factor signalling
pathways during carcinogenesis. At the level of the cell membrane, expressive changes in
receptors are more commonplace than mutations but the mechanisms responsible for this
are poorly understood. Colon cancers frequently over express EGFR, ERB2 (Shirai,
H.,1995), PDGFR ( Bellone, G.,1997), Met (Liu, C.,1992) and IGF-1R ( Freier, S.,1999);
and under express TGF(3RII ( Zhang, T., 1997) and E-cadherin (Ilyas, M., 1997) at
different stages in their evolution. Similarly, at the level of the cytoplasmic signalling
pathways - ras/raf-l/MAPK, PI3K/Akt, APC/|3-catenin/Tcf and TGF|3RII/SMAD - there
are numerous mutations and expression changes at different stages of neoplasia.
However, some of the downstream target genes of the RTKs and their signalling
pathways - e.g. fos, cyclin D1 and bcl-2 - are over expressed from the early stages of
tumour initiation (Arber, N.,1996), (Shpitz, B.,1999), (Sinicrope, F.A.,1995). The
combination of mutations and expressive changes in the signalling pathways required to
bring about such a change in gene expression in the early tumour cell are unknown. It
also leads one to question what purpose later mutations in the upstream pathways serve?
Here, experimental models provide a useful analogy. For example, in transgenic models
the over expression of growth factors or their receptors results in the over expression of
target genes, cell hyperplasia and disordered differentiation similar to that of tumour
initiation (Westermark, B., 1991), (Di Fiore, P.P., 1987), (Li, M.,1992), (Pietrzkowski,
Z.C.,1992), (Tsarfaty, L.,1994). On its own however this over expression of growth
factors or their receptors is insufficient to confer the fully transformed phenotype. Indeed,
the withdrawal of growth factors and cell matrix anchorage or p53/TGF(3 stimulation at
this stage will result in the terminal differentiation or apoptosis of these cells (Wylie,
A.H., 1987). Tumour progression requires additional mutations in the cell's signalling
pathways. Ras mutations have long been held up as an example of this, being able to
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abrogate the requirement for some growth factor receptors such as EGFR but not for
others such as IGF-1R (Falco, J.P.,1988). Equally, many other mutations in the signalling
pathways described above are thought to further reduce the cancer cell's dependency on
growth factor, cell anchorage and genomic integrity controls necessary for tumour
progression. Of note however, in spite of multiple mutations and unlike other RTKs,
many cancer phenotypes display a continued dependency on the IGF-1R and its
signalling pathways (see below). In light of this, the association of its signalling pathways
with oncogene / tumour suppressor mechanisms and its important role in controlling cell
cycle entry and differentiation, the IGF-1R is an interesting model gene with which to
examine the process of tumourigenesis.
1.5. The IGF system
The insulin-like growth factors (IGF-I, IGF-II), binding proteins (IGFBP1-10+)
and receptors (IGF-1R, IGF-2R) comprise a highly conserved endocrine and autocrine
signalling system which is utilised by most cell types. The insulin-like growth factor type
1 receptor has been shown to play key roles in embryology (Werner, H., 1989), (Fiu, J.P.,
1993); cell cycle restriction point progression (Stiles, C.D.,1979), (Baserga, R.,1993);
cell survival under stress (Harrington, E.A.,1994), (Valentinis, B.,1999); cell
differentiation (Rosenthal, S.,1995), (Jin, S., 2000) and cell adhesion (Mauro, 2004).
Prior studies have shown that embryonic stem cells express high levels of growth
factor receptors such as the IGF-1R (Werner, H., 1989)(Macaulay, V.M.,1992). The
expression levels of growth factor receptors in adult stem cells has not been examined,
primarily because of the difficulty in identifying adult stem cell compartments (the
colonic crypt is therefore an excellent model for examining stem cell maturatrion). Most
adult differentiated cells express low levels of growth factor receptors but the timing and
mechanisms underlying these changes in gene expression are unknown.
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A role for the IGF-1R in cancer appears no less important. Many cancers have
now been found to over express the IGF-1R or its ligands, IGF-1 and IGF-II (Macaulay,
V.M., 1992), (Zhang, L., 1997). There is now extensive clinical and experimental data to
indicate an important role for the IGF-1R in neoplasia of the breast (Surmacz, 2000),
prostate (Djavan, 2001), colon (Giovannucci, 2001), lung (Wu, 2000), pancreas (Korc
1998), liver (Scharf, 2001), ovary (Druckmann, 2002), bladder (Hursting, 2001) and
brain (Zumkeller, 1999). However, there is also evidence to show that the IGF-1R is not
as highly expressed in more advanced cancers of the colo-rectum (Nakamura, M., 2004),
breast (Schnarr, B., 2000)(Pennisi PA, 2002) and prostate (Hellawell, G., 2002). The
reasons for this are unknown but the timing of these expressive changes in the IGF-1R
during neoplasia of the colo-rectum are examined in this thesis.
Serum IGF levels have also been correlated with cancer incidences for colon
(Klein, I., 1982), (Barzilay, J., 1991), (Ezzat, S„ 1991), (Ron, E.,1991), (Ladas, S.D.,
1994), (Ma, J., 1999), prostate (Grimberg, A., 1999) and lung cancers (Yu, H., 1999). A
role for the IGF-1R is also evident in transgenic models of tumour initiation (Sell, C.,
1993),(Christophori, G.,1994), (DeGiovanni, J., 2000). However, the role of the IGF-1R
in human tumour initiation and progression has yet to be defined and is examined in this
thesis.
1.6. The IGF-1R gene
The IGF-1R gene was first cloned in 1986 by Ulrich and colleagues ( Ullrich A,
1986). The gene maps to 15q25,26, has 21 exons and is more than 100 kb in length.
Exon 1 has a 1038-bp 5'-UTR with a single initiator ( Abott, A.M., 1992). The a-
subunit maps to exons 1-11 and the (3-subunit maps to exons 12-21. There is a single
identified splice-variant at the end of exon 14. Exon 21 has a >840 bp 3'-UTR.
There is considerable exon size and sequence homology with the insulin and
insulin-related receptors. Sequence homology varies between 80-95% for exons 16-20
which encode the tyrosine kinase domain of the |3-subunit; 48% for exons 1-4 encoding
28
the cys-rich ligand-binding domain of the a-subunit (which is also homologous in the
EGFR and HER2); to 27% in exon 14 which encodes the trans membrane domain in the
b-subunit. The C-terminal 108 aa hydrophilic tail of the [3-subunit in exon 20 displays the
greatest divergence.
Figure 1.5 The IGF-1R gene
IGF-1R gene map
Exons
1 2 3 4 56 78 91011 14 16 18 20 21
kbp 20 40 60 80 100
1.7. IGF-1R transcripts
Given the sequence homologies between 1GF-1R, IR and IRR, it is conceivable
that these species might cross-hybridize with antisense 1GF-1R probes. This was
addressed (Ullrich, A., 1986) by sequential hybridisations of RNA from several tissues
with an 1GF-1R probe generated from a 2.8 kb EcoRI fragment of the IGF-1R sequence
(exon 1-11) and compared with hybridisations with an IR probe. This demonstrated IGF-
1R hybridisations with a major transcript at 1 lkbases and a minor transcript at 7 kbases
whilst IR hybridisations were at 10.3, 9.6, 8.5 and 6.7 species in human placenta and
were without any evidence of cross-hybridisation in either assay. Also, Southern
hybridisations showed single bands after restriction digests so that these species were
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derived from a single gene. The IGF-1R minor 7 kb transcripts occurred in placenta but
not in other adult tissues.
1.8. The IGF-1R peptide
A 4101 nucleotide reading frame translates a 1367 aa NH2-signal peptide-a-
subunit- (3-subunit-COOH preproreceptor. Post translational cleavage and glycosylation
results in subunits of ~135,000 Mr (a-subunit) and ~90,000 Mr ((3-subunit). The IGF-1R
is processed to exist as a 350kda 02^2 heterotetramer with the a- and |3-subunits attached
by disulfide bonds (Grunfield, C.,1985).
The a-subunit region contains a 24-rich cys region from residues 148 to 302,
representing the ligand-binding domain.
The |3-subunit has an extracellular domain (residues 711-905), a 24 aa
hydrophobic sequence (residues 906-929) representing the trans membrane domain, and a
407 aa cytoplasmic domain. Tyrosine kinase domains are located between residues 973
and 1229. A conformational change in these domains on ligand-binding results in ATP-
binding at Gly976-Gly981 and lysl003 and the subsequent phosphorylation of residues
tyrl 131, tyrl 135 and tyrl 136. Each P-subunit then transphosphorylates the other leading
to phosphorylation of tyr950 in the juxtamembrane region and tyrl250, tyrl251 and
tyrl316 in the carboxyl-terminal domain.
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The IGF-1 R is expressed to varying degrees in all tissues and cells in culture. Its
principal determinants of expression however appear to be :
a. Developmental
High IGF-1R levels are expressed in embryonic stem cells and these decline in
the perinatal period to reach their lowest in most differentiated tissues. (Werner, H.,
1989), (Chernausek, S.D.,1987). Most differentiated tissues such as the liver express low
IGF-1R levels in the adult but some, such as kidney and muscle express higher levels.
b. Proliferation, differentiation and cell survival
IGF-1 receptors have been shown to increase in number between the G1 and S
phases of the cell cycle in Burkitt lymphoma cells (Hartman W, 1988); to decrease in
number during differentiation in 3T3 fibroblasts, CaCo-2 and HT29 colon carcinoma
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cells (Modan-Moses, D.,1998), (Zarrilli, R., 1994), ( Garrouste, L., 1997); and to
transiently upregulate then undergo downregulation when neuronal cells are
progressively exposed to apoptotic cell injury (Roschier, M., 2001). As in the embryonic
stem cell, the IGF-1R appears to be an important component of the adult cell's control
apparatus.
c. Hormonal regulation
Hormonal regulation also impacts upon IGF-1R expression. For example,
physiological concentrations of oestradiol can increase MCF-7 breast cancer cells' IGF-
1R expression and growth (Stewart, A.J., 1990) whilst progestins decrease IGF-1R and
growth in another breast cancer cell line, T47D (Papa, V., 1991). In SH-SY5Y
neuroblastoma cell lines, TPA can increase IGF-1R expression and neurite formation
(Ota, A., 1989), whilst ovarian and cartilage cells increase their IGF-1R expression and
growth in response to FSH and GH respectively (Hernandez, E.R., 1991), (Isaksson,
O.G.P., 1991). These changes may be explained by the hormone-responsive regions of
the IGF-1R promoter.
d. Growth factor regulation
PDGF and FGF strongly induce IGF-1R in 3T3 cells (Clemmons, K.R., 1980)
and other mesenchyme-derived cells such as vascular smooth muscle cells (Ververis, J.J.,
1993). This may reflect the roles of these receptors in the cell cycle as discussed
previously. IGF-1 on the other hand can suppress IGF-1R expression in cell cultures
including 3T3 fibroblasts, endothelial, lymphoid and thyroid cells (Rosenfield, R.G.,
1980), (Rosenfield, R.G.,1982).
1.10. The IGF-1R promoter
The human IGF-1R promoter has been sequenced (Cooke, D.W., 1991) to the
extent of its 480 bp 5'-flank and 1038-bp 5'-UTR. Both regions are GC-rich (75% and
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68% respectively) with numerous Spl binding sites (-CCCGCC-) (Mitchell, P.J., 1989).
There are no TATA or CCAAT elements. Instead a single initiator motif
(5'-GCCCCCAGTGTGTGGCA-3') is thought to act in concert with the Spl sites to
direct high levels of basal transcription as previously described elsewhere (Smale, S.T.,
1989).
The GC-rich TATA-less promoter of the IGF-1R promoter bears some similarity
in this respect to the promoters of housekeeping genes such as the insulin receptor (Seino
S, 1989). However, unlike these promoters, it has a single initiator motif more commonly
associated with the promoters of developmental and differentiation genes (Biggin,
M.D.,1988), (Perkins, K.K.,1988). Additionally, the IGF-lR's long 5'-UTR is a feature
shared by genes that regulate cell proliferation such as growth factors and several cellular
oncogenes (Kozak, M., 1987).
The IGF-1R promoter exhibits high basal activity in reporter assays (Werner, H.,
1992). As IGF-1R gene expression in most adult differentiated cells is low the promoter
must be under some form of inhibitory control. In the rat IGF-1R gene, the -494/-331
fragment, which has four Spl sites, can have 90% activity. In contrast, the -331/-135 and
-135/-26 fragments can each exhibit between 11% and 70% promoter activity depending
on the transfected cell type. Thus, promoter activity is the result of combinatorial cis-
elements of mostly Spl sites acting in the proximal 5'-flanking region. This activity can
in turn be enhanced or inhibited by other trans-regulators in the 5'-flanking and 5'~UTR
regions. For example, the 5'-flanking region has a potential binding site for the AP-2
transcription factor (5'-CCCCACGC-3') at positions -136 to -129 which may explain the
responsiveness of the gene to cAMP (Adashi, E.Y., 1986), (Imagawa, M., 1987), phorbol
esters (Ota, A., 1989), (Roesler, W.J., 1988) and FSH (Adashi, E.Y., 1986).
As well as the above cis-regulatory elements, the 5'-flanking region contains
several growth factor-responsive regions. The -124 bp region of the 5'-flanking region
proximal to the initiator has been found to be a PDGF- and SVLT-responsive element in
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the rat IGF-1R promoter (Rubini, M., 1994). This site can complex E2F, cyclin A and
pl07 as well as Spl.
C-myc is induced primarily by PDGF and it is notable that the IGF-1R promoter
in the rat but not in the human contains a c-myc E-box domain (Halazonetis, T.D., 1991).
Nevertheless, N-myc is able to trans-activate the proximal 5'-flank region at -420/+60 in
the human IGF-1R promoter (Chambery, D., 1999) suggesting that some form of direct
or indirect response element exists. The myc nuclear phosphoprotein also binds and
activates other promoters containing E-box motifs along with cyclins A and E (Jansen-
Durr, P., 1993). Its expression closely correlates with those genes expressed during
embryogenesis and during proliferation (Mugrauer, G., 1991).
In addition to the above, a putative IGF-I-responsive element homologous to that
in the elastin promoter also lies at -583/-555 (Wolfe, B.L., 1993). Although the
mechanism of action of the above is not understood, they may represent a means of IGF-
1R promoter autocrine feedback control.
The 5'-flank and 5'-UTR are targeted by the tumour suppressors WT-1 and p53.
Wt-1 suppresses the promoter by binding the 5'-GCGGGGGCG-3' consensus sequence
located at -294/-286 and 919/927 (Werner, H„ 1994),(Werner, H., 1993). The WT-1 gene
encodes a zinc-finger protein of the Cys2-His2 type with homology to the EGR-1
transcription factors (Gashler, A., 1995). It targets and inhibits the promoters of several
growth factors and growth factor receptors including PDGF, IGF-II, TGF(31, EGFR and
IGF-1R and is itself induced during epithelial and embryonic stem cell differentiation
(Scharnhorst, V.,1997). Wild type p53 can also suppress the IGF-1R promoter, possibly
through complexing with and inhibiting the interaction of the TBP component of the
TFIID transcription complex (Werner, H., 1996) or by complexing in a similar manner
with Spl (Ohlsson, C., 1998). Like the myc oncogenes, the WT-1 and p53 may thus
represent possible means for tumour cells to over express the IGF-1R.
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Figure 1.7 Graphic of the human IGF-1R promoter






-404 Sp1 -371 ETF
-331 GCF
7-476/-188 bFGF
-317 Sp1 -294 WT-1 response element
-271 Sp1
-227 Sp1 Sp1~p53 -420/60 Major














842 Sp1 919 WT-1
1039
ATG 1 f Translation
1.11. IGF-1R transcription and translation
Although its translative and post-translative control mechanisms are not
understood, 1GF-1R membrane peptide expression most closely correlates to transcription
in all the studies where it has been assessed (Lowe, W.L., 1989); (Ota, A., 1989);
(Ohlsson, C., 1998). In keeping with the majority of membrane receptors, most of the
synthesised IGF-1R exists in the cytoplasmic pool and the dynamics of its processing
between endoplasmic reticulum and membrane are again not understood.
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1.12. Ligand binding of the IGF-1R
IGF-1 binds with high affinity the IGF-1R which has 2 to 3 times lower affinity
for IGF-II and 100 times lower affinity for insulin (Czech, M.P., 1989). Ligand binding
results in a conformational change in the catalytic loop domain of the tyrosine kinase
region, ATP binding at Gly976-981/Lysl003 and subsequent phosphorylation of tyrl 131,
tyrl 135 and tyrl 136. This leads to autophosphorylation of the juxtamembrane tyr950 and
carboxyl-terminal tyr 1250,1251,1315 / serl280-1283 domains. These phosphorylated
residues provide docking sites for the primary substrates described above.
Phosphorylation of the juxtamembrane domain also causes IGF-IRs to aggregate and
internalise within clathrin-coated micro vesicles. Although this function is not critical for
some of the signalling pathways, it is critical for IGF-lR-dependent malignant
transformation (Prager, D., 1994).
1.13. IGF-1R signalling
The IGF-1R is a powerful inducer of the classical ras/raf-l/MAPK, PI3K/Akt and
|3-Catenin/Tcf pathways (as described above). She, Crk and several isoforms of IRS bind
via their SH2 domains to a NPXpY motif (that includes tyr950) in the juxtamembrane
region of the (3-subunit (Gustafson, T.A., 1995),(Beitner-Johnson, D., 1995). IRS also
binds the tyrosine kinase domain tyrl 131-1136. Once bound these proteins become
phosphorylated by IGF-1R tyrosine kinases. Consequently, these then bind Grb2 (growth
factor receptor-bound protein 2) which then binds inSOS (the mammalian Son of
Sevenless)(Pruett, W., 1995), (Tanaka, S., 1994). This then loads GTP onto Ras protein
G and hence activates the Ras/Raf/MAPK pathway. IRS also binds the p85 subunit of
phosphoinositide 3'-kinase (PI3K) via its SH3 domain and thus can activate the PI3K/Akt
pathway (Kulik, G., 1997) whilst other pathways such as (3-Catenin/Tcf have been shown
to be secondarily recruited through signalling intermediaries such as GSK3|3 (Playford,
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M.P., 2000). Consequently, IGF-1R signal transduction through the MAPK, PI3K and (3-
Catenin/Tcf cytoplasmic cascades can have diverse effects from the trans activation of
growth response genes such as myc, fos, jun and cyclin D1 (Rosenzweig, S.A., 1993),
(He T.-C., 1998), (Rosenthal, S.M., 1995), (Tetsu, 0.,1999) to the regulation of pro- and
anti apoptotic cytosolic substrates such as BAD and Bcl-2 (Datta, S.R., 1997). Although
these pathways might explain the proliferative and anti-apoptotic activities of the IGF-
1R, they do not appear to fully explain the IGF-lR's role in differentiation and cell
transformation. Evidence supporting this has come from mutational analysis.
1.14. IGF-1R mutational analysis
Mutational analysis has shown the domains of the 1GF-1R are functionally
distinct. The functions of mitogenesis and anti-apoptosis can be shared by the tyrosine
kinase domain (Gronborg, M., 1993), (Li, S., 1994) whilst the juxtamembrane and c-
terminus domains of the 1GF-1R are obligate for cell differentiation and transformation
(Surmacz, E., 1995), (Valentinis, B., 1999). An unidentified mechanism and/ or
substrate-binding involving the juxtamembrane domain and the sequence 1245-1310 of
the c-terminus are required for cell differentiation and transformation. The signal
peptide 14.3.3 can bind the c-terminus at serl280,l,2,3 and can also bind to IRS-1
(Craparo, A., 1997). Although it can signal via IRS and BAD, much of its downstream
signalling has yet to be elucidated. Whether it can explain the differentiating and
transforming functions of the IGF-1R is unknown. Potentially interfering with this part of
IGF-1R signalling may have significant effects upon differentiation and cell
transformation without affecting cell proliferation.
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Figure 1.8 IGF-1R mutational analysis and mitogenesis / apoptosis vs.
differentiation / transformation functions











































1.15. The IGF-1R and cell function
Proliferation
As described above, most cells require a combination of PDGF (or EGF/FGF) and
IGF-1 to support proliferation in serum-free medium whilst individual growth factors on
their own fail to support growth (Stiles, C.D., 1979), (Scher, C.D., 1979), (Cristifalo,
V.J., 1989).
The IGF-1R and cell survival
The IGF-lR's role in cell survival might result from its role in MAPK- and PI3K-
mediated cell cycle advancement thereby preventing cellular differentiation, senescence
and cell death. But, there is also evidence from in vitro studies that IGF-1R may also
direct PI3K-, MAPK- and 14.3.3-mediated anti-apoptotic signalling via BAD, Bcl-2 and
Bcl-xL (Kulik, G., 1997) (Valentinis, B., 1999)
Some fastidious non-transformed cells are entirely dependent on IGF-1 for
survival. Haematopoietic cells and neuroglial cells for example exhibit an absolute
requirement for IGF-1 (Huang, S., 1992), (Ratajczak, M.Z., 1994), (Bozyczko-Coyne, D.,
1993), (Drago, J., 1991), (D'Mello, S.R., 1993). In other cell types, IGF-1R can inhibit
apoptosis induced by loss of extra-cellular matrix attachment (Valentinis, B., 1999),
serum withdrawal (Parrizas, M., 1997), IL-3 withdrawal (McCubrey, J.A., 1991), c-myc
over expression (Harrington, E.A., 1994), TGF|31 (Hsing, A.Y., 1996) , p53 activation
(Prisco, M., 1997) and ionising and non-ionising radiation (Kulik, G.,1997).
Although cells require PDGF/EGF and IGF-1 for proliferation, GO cells are
largely dependent on a functional IGF-1 R for survival in the face of cell stress. For
example, whilst IGF-1 can rescue 3T3 cells from c-myc induced apoptosis, PDGF is less
effective and EGF is ineffective (Harrington, E.A., 1994). This difference appears more
pronounced if the cell has been previously transformed or stressed in some manner. For
example, only IGF-1 can acutely prevent apoptosis of BALB/c3T3 cells in serum-free
conditions (Tamm, I., 1990).
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The IGF-1R and differentiation
Differentiation appears to take some of its cues from the cell cycle and the IGF-
1R. IGF-1R signalling via the oncogenic homologues Rb and Crk has been implicated in
differentiation (Rosenthal, S.M., 1995), (Jin, S., 2000). In other models of
differentiation, including those of the 3T3-L1 preadipocyte (Student, A.K., 1980), L6E9
skeletal myoblasts (Rosenthal, S.M., 1995) and HT29/CaCo-2 colon carcinoma cells
(Garrouste, F., 1997)(Augernon, C., 1984), differentiation in some cellular contexts can
be induced by IGF-1. In these models, IGF-1 can initially cause confluent GO growth
arrested cells to re-enter G1S and undergo on average a further two rounds of mitosis; a
process known as "mitotic clonal expansion" (Bernlohr, D.A., 1985). The resulting DNA
replication and chromatin remodelling are thought necessary to render nucleosomal DNA
and the appropriate promoter elements accessible to the transcription of differentiation
genes. These transcripts and the ensuing events of differentiation are poorly understood
(Tontonoz, P., 1994) (Flwang, C.S., 1996). It is recognised however that differentiation is
synchronised with a post-clonal expansion downregulation in IGF-1R (Garrouste, F.,
1997) as one might expect from the embryology studies. Once differentiated, normal cell
lines are unable to re-enter the cell cycle by presumably being unable to re-express the
genes (such as the IGF-1R) that are necessary for this. In contrast, transformed cells such
as HT29 and Caco-2 cells can, on occasion, re-enter the cell cycle after repassaging from
the differentiated state although interestingly they initially loose their ability to survive as
inoculates in vivo during the early stages of this process (Augernon, C., 1984). In other
words, differentiated tumoural cells can undergo clonal expansion but it may require
several rounds of mitosis, if at all, before they can properly re-express cell survival genes
such as IGF-1R.
The IGF-1R and cell adhesion
Recent reports have increasingly implicated a role for the IGF-1R in cell adhesion
as discussed above (Mauro, 2004). The internalised IGF-1R forms a tripartite complex
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with p-catenin and E-cadhern to effectively reduce membrane E-cadherin but also to
control gene transcription of myc. The details of this mechanism and some of the other
genes controlled have still to be elucidated but it is becoming clear from in vitro and in
vivo studies of human colon cancer cell lines and human colon cancers that a reduction in
IGF-1R expression predicts a loss of cell adhesion and metastasis repectively (Playford,
2000),(Nakamura, 2004).
The IGF-1R and transformation
It has long been recognised that over expression of growth factor receptors can
result in cellular transformation with growth supported solely by the respective ligands.
This has been shown to be true for PDGFR (Fantl, W.J., 1989), (Westermark, B., 1991);
EGFR (Di Fiore, P.P., 1987), (Pietrzkowski, Z., 1992), (Velu, T.J., 1989); FGFR (Li, M.,
1992); HGFR met (Tsarfaty, I., 1994); IGF-1R (Kaleko, M„ 1990),(McCubey, J.A.,
1991), (Pietrzkowski, Z., 1992); and insulin receptors (Randazzo, P.A., 1990). However,
receptor knockout studies reveal some interesting differences between receptor subtypes.
IGF-1R knockout cells are completely resistant to transformation by oncogenes: SV40T,
Ras, Raf, v-Src and BPV E5 (Sell, C., 1994), (Coppola, D„ 1994),(Valentinis, B„ 1997)
as well as by the over expressed EGFR, EGF, PDGFR, PDGF and insulin receptors
(Coppola, D., 1994), (DeAngelis, T., 1995), (Reviewed- Baserga, R.,1995). In contrast,
other receptor knockout cells such as those for the EGFR can undergo transformation by
say, ras oncogenes (Hansen, L.A., 2000), (Sibilia, M., 2000).
1.16. The 1GF-1R and animal models
Transgenic studies provide some clues to the role of the IGF axis in embryology
and transformation. Deletion of the IGF-1R in mice by homologous recombination results
in embryos which are 45% the size of wild type embryos and are nonviable at birth with
defects noted during the later stages of differentiation of the nervous system, skin and
bones (Baker, J., 1993), (Liu, J.P., 1993). These knockout cells, although able to grow,
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are entirely resistant to transformation. EGFR knockout (-/-) mice in contrast are born
with immature epithelium of the gut, liver and pancreas and succumb to necrotising
enterocolitis within the first few days of life (Miettinen, P.J., 1995). However, cells
derived from these embryos are able to undergo malignant transformation.
Over expression animal studies are very much limited by the promoter and the
relevant target tissue. For example, over expression of IGF-1 driven by a bovine keratin
promoter in transgenic mice results in tumours of the skin and prostate where the
transgene is expressed (DiGiovanni, J., 2000). Over expression of IGF-I1 driven by the
MUP promoter in transgenic mice results in the frequent development of tumours by 18
months of age- notably hepatocellular carcinomas and lymphomas (Rogler, C.E., 1994).
Similarly in SV40T-transgenic mice (SV40T is known to trans activate the IGF-1 R and
IGF-II promoters) islet cell hyper proliferation and islets tumours correlate with IGF-II
over expression (Chrisofori, G., 1994). An IGF-1R over expression model has not been
developed but all the indications are that the IGF-1R has a perceived role in co-ordinating
proliferation and differentiation in the embryo.
1.17. An accounting
The pertinent points from the above discussion can be summarised :
1. The IGF-1R is highly expressed in embryonic stem cells but is expressed at low levels
in most (but not all) adult differentiated tissues. Most cancers highly express the IGF-1 R
but some advanced cancers express comparatively lower levels. The reasons for these
changes in IGF-1R expression are unclear. Expressive or mutational changes in p53, WT-
1 and myc have been suggested as possible reasons for changes in IGF-1R transcription
in some cancers.
2. The IGF-1R signalling cascade is an important determinant of cell cycle G1S
progression, cell differentiation, cell survival and cell adhesion. Components of this (and
other RTK) signalling cascades are targeted by cancer mutations.
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3. IGF-1R functionality is a requisite for experimental cell transformation.
4. The colon crypt-cancer model is ideally suited to examine the temporal expression of
genes during the evolution of cancer.
1.18. Prior studies
Ligand binding studies had initially demonstrated the presence of IGF-1 receptors
with saturable kinetics and with the correct molecular weight in both normal (Pillion,
D.J., 1989), (Rouyer-Fessard, C., 1990) and tumoural colonic mucosa specimens (Guo,
Y.-S., 1992). However, the variances arising from the membrane microsomal preparation
technique means that direct comparisons between studies for normal and tumoural
specimens has not been possible.
Comparison of different ligand binding studies (Guo. Pillion. Rouver-Fesard)
Scatchard analysis
Kd(nmol/L) Bmax (xl05 sites/cell)
HCT-116+ 1.45+/-0.2 1.5+/-0.12
Colo-205+ 1.07+/-0.02 1.96+/-0.02




+,*.$ These assays were from different studies with different microsomal preparation
techniques and demonstrated considerable inter-study variability in their Kds for colonic
epithelial microsomal preparations.
+( Guo Y-S, Narayan S, Yallampalli C & Singh P., 1992)
*(Pillion D, Haskell JF, Aitchison J, Ganapathy V & Leibach FH., 1989)
$(Rouyer-Fessard C, Gammeltoft S, Laburthe M.,1990)
Also, and significantly, tissue dissection with ligand binding (Laburthe, M., 1988) and
autoradiographic mapping (Heinz-Erian, P., 1991) have demonstrated IGF-1R
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expression in the basal proliferative crypt as opposed to the upper differentiated crypt in
the rat gastrointestinal epithelium.
Ligand binding studies on colon cancer cell lines have also been revealing. Here
it has been found that different cell lines express different levels of the IGF-1R (see
above). For example, HT-29 cells which have p53 and APC mutations have been found
to express lower levels of IGF-1R in comparison to clO cells which have wild type APC
and (3-catenin (Playford, M.P., 2000). However, as cancer cell lines frequently accrue
diverse mutations during culture and mutational screening of these cell lines is far from
complete, such comparisons must be treated with caution. Much more consistent is the
finding that differentiation in HT29 and Caco-2 cells is also accompanied by reduced
expression of the IGF-1R and a loss of tumourigenicity in vivo (Garrouste, F., 1997),
(Remacle-Bonnet, M.M., 1992), (Augernon, C., 1984), (Zarilli, R., 1996). However there
are fundamental difficulties in comparing these in vitro studies to human tissues - both
show diverse cell heterogeneities and differences in cellular environment and there are
practical difficulties in culturing normal enterocytes.
The IGF-1R has been assayed in several tissue-based studies comparing normal
and tumoural colonic mucosa. IGF-1R RNA analysis presents difficulties because of the
low copy number and high molecular weight of transcripts. Zenilman and Graham
(Zenilman, M.E.,1997) assayed 1GF-1R mRNA by means of a quantitative PCR but were
unable to find any difference between normal and tumoural mucosa given the limitations
of the assay. Freier and Raz (Freier, S., 1999) in contrast used RNAse protection assays
to determine that IGF-1R and IGF-II were over expressed in 6 colon cancers in
comparison to normal epithelium. These studies do not of course examine IGF-1R
expression in a cell specific manner and take no account of the heterogeneous nature of
tissues. With the development of antibodies to the IGF-1R, Hakam and Coppola (Hakam,
A., 1999) found that 8/12 adenomas, 34/36 carcinomas and no normal (differentiated)
mucosal specimens stained positively for the IGF-1R. But, how IGF-1R expression might
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be related to the processes of tumour initiation and progression was not addressed in this
study.
1.19. The hypothesis and aims
Given the foregoing discussion, we are led to ask when and how the IGF-1R is
highly expressed in colo-rectal neoplasia ? If high IGF-IR expression is observed at a
particular stage in neoplasia, then is this as a consequence of a recognised trans regulator
or some other process ?
The primary aim of this thesis is therefore to examine the expression profile of the
IGF-IR in the colo-rectal polyp-cancer sequence to elucidate the timing of high IGF-IR
expression during early neoplasia and also to elucidate if a change in IGF-IR expression
occurs during later stage neoplasia. A secondary aim is to examine the expression of IGF-
1R trans regulators to determine if these or the pattern of IGF-IR expression in the crypt-





The main body of the experimental work was conducted in three departments of
the University of Edinburgh on site at the Western General Hospital, Crewe Road,
Edinburgh :
1. The department of Surgical Oncology, growth factor laboratory under the supervision
of Dr. Fouad K. Habib and Professor Colin S. McArdle;
2. The department of Molecular Medicine under the supervision of Dr. Karen Chapman
and Professor Johnathon Seckle;
3. The department of Pathology under the supervision of Dr. Margaret Maclntyre.
2.2. Materials
Tissue specimens
Fresh colo-rectal resection specimens were obtained from the theatre lists of Mr.
Graeme Wilson, Mr. Malcolm Dunlop and Mr. David Hamer Hodges at the Western
General Hospital. The specimens were processed fresh in the department of Pathology at
the Western General Hospital by Dr. Margaret Maclntyre. Additionally, some fresh and
archival specimens were also obtained from Mr. David Bartolo, department of Surgery at
the Royal Infirmary and Dr. Hugh Gilmour and Dr. Juan Piris, department of Pathology
at the Royal Infirmary of Edinburgh.
General consumables
The majority of chemicals used in preparative work were of molecular biology
grade and were purchased from Sigma Aldrich. Molecular biology reagents were almost
exclusively purchased from Promega. Nuclease-free Eppendorf tubes were purchased
from Sarstedt Ltd., Leicester.
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Molecular biology
The plasmid pGEM-T.Easy used to clone the IGF-1R construct was purchased
from Promega, UK. The IGF-1R primers were synthesised by Oligonucleotide Synthesis
Service, ICRF Clare Flail Laboratories, Herts.
pTri-c-myc and pTri-(Lactin (Ambion, Austin, Texas) were purchased from AMS
Biotechnology, Witney, Oxfordshire.
pGem-3Z-WT-l construct was a kind gift from Dr. David Housman,
Massachusetts Institute of Technology.
Anti-human IGF-1R a-subunit IgY antibody and a-subunit synthetic peptides
(Upstate Biotechnology Inc, Lake Placid, New York) were purchased from TCS
Biologicals Ltd., Botolph Claydon, Buckingham. Anti-IGF-IR mouse IgG monoclonal
(Oncogene Research Products, Cambridge, Massachusetts) was purchased from
Calbiochem-Novabiochem, Beeston, Nottingham.
2.3. Methods - Tissue specimens and preparation
Fresh resective specimens were transported from the operating theatre to the
pathology laboratory on water ice where they were processed within half an hour of
resection by the pathologist.
Colonic resected specimens were washed, opened and pinned out. Between 1 to
2g of the exophytic luminal aspect of the cancer specimen was taken and washed in ice-
cold saline. Separate specimens were then snap frozen and subsequently stored in liquid
nitrogen for RNA and protein analysis or placed in 10% formaldehyde for histological
analysis or further washed in saline and placed in RPMI supplemented growth medium
for primary culture. Rectal cancers were treated separately by harvesting from within the
lumen prior to fixation and coronal sectioning of the main specimen. Polyp specimens
when pedunculated were taken from the aspect distant to the stalk. Normal colonic
mucosa at least 10cm proximal or distal to the tumoural specimen was dissected free
from the underlying muscularis mucosa, and then treated similarly to the tumoural
specimens.
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Archival specimens from the previous 6 months were sourced from the catalogues
of the departments of Pathology at the Western General Hospital and the Royal Infirmary
of Edinburgh.
2.4. RNA analysis - Isolation of RNA from tissue specimens
Total RNA was isolated from gross tissue specimens using a modification of the
acid-guanidium- phenol-chloroform method of Chomczynski and Sacchi (1987). In order
to maintain RNA integrity, all solutions and glassware were prepared by treating
overnight with 0.05% diethyl pyrocarbonate (DEPC) and then autoclaving for 15 minutes
at 151b/sq.in. on the liquid cycle.
Up to lg of snap frozen tissue was used as per the following protocol. The frozen
tissue was powderised using a Mikro-Dismembrator II (B. Braun Biotech International
GmbH, Melsungen, Germany) fitted with a 7ml teflon flask and stainless steel grinding
ball, both pre-chilled in liquid nitrogen. The specimen was disrupted at full power for 15
seconds. The resulting powder was then homogenised ( Brinkman, Polytron ) for 15
seconds and lysed on ice for a further 10 minutes in 12ml of freshly prepared ice-cold
GTC extraction buffer in a 50ml Corning centrifuge flask.
GTC buffer: 4M guanidium isothiocyanate
25mM sodium citrate, pH7.0
2% mercaptoethanol
1.2 ml of 2M sodium acetate, pH4, was then added to the crude homogenate and mixed.
12 ml of phenol-chloroform-isoamyl alcohol (PC) were then added, mixed by vortexing
and chilled on ice for a further 15 minutes.
PC solution : 10ml water saturated phenol, pH 4
2 ml chloroform-isoamylalcohol (49:1)
The suspension was then centrifuged at 10,000 r.p.m for 20 minutes at 4°C with a
swinging bucket rotor. The top aqueous phase was then transferred to Eppendorf tubes
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where it was mixed with an equal volume of Isopropanol and incubated overnight at -
20°C to precipitate the RNA. This was pelleted by microcentrifugation at 13,000 r.p.m
for 20 minutes at 4°C. The pellets were resuspended in 100 pi of GTC buffer, the
samples pooled and reprecipitated with another equal volume of Isopropanol for at least 2
hours at -20 °C. The sample was then centrifuged at 13,000 r.p.m. for 10 minutes at 4°C
and the RNA pellet then washed twice in 500 pi of 75% ethanol and respun at 13,000
r.p.m at 4°C for 5 minutes. The supernatant was then aspirated and the RNA pellet air
dried for 30 minutes at room temperature and then suspended in 100-500 pi of nuclease-
free water.
The RNA yield was determined spectrophotometrically by diluting a 5pl RNA
sample aliquot in 4.995 ml of DEPC treated water. An OD260 of 1=40 pg/ml whilst an
OD260/OD280 ratio of 2 corresponds to a pure sample. If the ratio was less than 1.7 then
the RNA was re-extracted with phenol-chloroform.
2.5. RNA analysis - mRNA purification, reverse transcription and polymerase chain
reaction
The basic polymerase chain reaction is an adaptation of that first described by
Saiki and is protocolled in the Promega Protocols and Applications Guide (3rd Edition,
1996). Because of the low copy number of the IGF-1R gene in normal colonic
epithelium, it became necessary to mRNA purify the samples and employ high cycle
numbers, limiting the reproducibility of quantitative PCR.
mRNA purification
A commercial system comprising biotinylated oligo(dT) isolation with
streptavadin/paramagnetic capture was utilised (PolyATract mRNA isolation System I,
Promega, UK).
2mg of total RNA was made-up to a total volume of 2.43ml in nuclease-free
water and heated to 65°C for 10 minutes. To this was added lOpl of biotinylated-
oligo(dT) probe and 60pl of 20X SSC (to make a 0.5X SSC solution) and the solution
allowed to cool to room temperature. The annealed mixture was then added to 0.5ml of
streptavadin-paramagnetic particles previously washed and suspended in 0.5X SSC. This
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was incubated at room temperature for 10 minutes and the particles captured then washed
four times in 1.5ml of 0.1 X SSC. The mRNA was then eluted in nuclease-free water and
the concentration and purity determined by spectrophotometry.
Reverse transcription
This protocol for cDNA synthesis is similarly a modification of that described in
the Promega Protocols and Applications Guide, lpg of mRNA was diluted in nuclease-
free water up to 5.4pl and heated to 70°C for 5 minutes before cooling on ice and pulsing
in a microfuge ready to be loaded into the following reaction mixture:
RT mix : 4pl of 25mM MgCb (previously heated to 65 °C)
2pl of 10X reverse transcription buffer (heated to 37 °C)
2pl of lOmM dNTP mix
2pl of rRNasin ribonuclease inhibitor (40 unitspl-1)
lpl of oligo(dT)15 (0.5pgpl-l)
0.6pl ofAMV reverse transcriptase (25unitspl-l)
(negative control with no RT)
total volume = 20pl
The tube was pulse vortexed and microfuged. First strand cDNA synthesis and
amplification proceeded by incubating at 42 °C for 1 hour. The RT was then denatured by
heating to 99°C for 5 minutes and this was followed by 5 minutes on ice.
PCR amplification of IGF-1R cDNA sequences
IGF-1R cDNA was analysed using the following primers locating to and spanning
the annotated exons :
Primers: IGF-lRsense 5'ACC CTT GAT TCT GTT ACT TC3'
IGF-1Ranti-sense AAT TCT TAC AGT GTC TCA TA
Product: 596 base pair, 1063-1659 of IGF-1R (exons 4-8 of a-subunit)
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Reactions were performed in a Hybaid thermal reactor using Promega Tfl Taq
DNA polymerase.
PCR mix : 20pl of cDNA (final [ )<10ngml')
lOpl of sense primer (50ngml ')(final [ |=lmM)
10pl of antisense primer
6pl of MgC12 (final [ J=1.5mM)
lOpl of 10X reaction buffer
2pl of dNTP mix
lpl of Taq DNA polymerase (final | ]=0.025uml')
total volume = lOOpl
PCR cycles : 40x
Melt 94 °C, 1minute
Anneal 52 °C, 1 minute
Extend 72 °C, 2 minutes
The products were then run on a 2% agarose gel prepared by melting 1.5g of Agarose NA
(Pharmacia) in 75ml of IX TBE. The molten agarose was cooled to ~40°C before adding
lpl of lOmgml1 of ethidium bromide and pouring into a sealed mini-gel tray with a 1.5
mm 16 well comb. Once set, this was placed into the submarine mini-gel apparatus
(Northumbria Biologicals Ltd.) and covered with 750ml of IX TBE. 18pl reaction
aliquots mixed with 2pl of DNA loading buffer (Sigma) were loaded alongside 20pl of
lOObp ladder (Promega) and the gel run at 50 volts for 3-4 hours before photographing
under UV transillumination.
5X TBE : 5.4% Tris-base
2.75% boric acid
lOmM EDTA, pH 8.0
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2.6. RNA analysis - Riboprobe manufacture
Fresh PCR products were TA cloned into the plasmid vector pGEM-T Easy
(Promega) as described by Storts and protocolled in the Promega Vector Systems
Technical Manual. This vector has single 3'-T overhangs at the insertion site which lies
within a (3-galactosidase coding region and is flanked by dual transcription / sequencing
start sites. Transformants are thus blue/white colour screened. Inserts were screened by
restriction analysis and sequencing prior to riboprobe synthesis.
DNA purification from gels
A silica gel based spin recovery kit (Hybaid Recovery TM ) was used for the
purification of IGF-1R cDNA PCR product from 0.8% low melting point agarose gels.
Briefly, the correctly sized PCR product derived from normal epithelium template cDNA
was cut from the transilluminated gel with a fresh blade and then heated to 55 °C for 5
minutes in 400pl of reconstituted silica gel in binding buffer in a spin filter tube ( Hybaid
Recovery TM). The filter was spun for 30 seconds and then washed twice with dilute
ethanol/wash solution before spinning dry. The DNA was then recovered by elution with
nuclease-free water and its concentration determined by spectrophotometry
TA cloning of PCR product
Insert-vector ligations were set up as below and run overnight at 4°C :
lpl of T4 DNA ligase 10X buffer
lpl of pGEM-T Easy vector (50ng)
lOng of PCR product (~1:1 vector:0.5kb insert ratio)
lpl T4 DNA ligase (3 Weiss units pi1)
nuclease-free water to a total volume of lOpl





Transformations using the vector ligation product
JM109 (Promega) high efficiency competent cells (stored at -70 °C) were used
with selection on LB/ampicillin/IPTG/X-Gal plates. Initially, the competent cells were
gently thawed for 5 minutes in an ice bath with gentle mixing by hand. 50pl aliquots of
these cells were then transferred into sterile pre-chilled 15ml Falcon tubes and to these
were added 2pl of the above ligation reactions. A control tube containing 0.1 ng of uncut
plasmid instead was also prepared to determine the transformation efficiency. The tubes
were gently flicked to mix then placed on ice for 20 minutes. The cells were then heat
shocked by placing in a water bath at exactly 42 °C for 45 seconds and then returned to
ice for a further 2 minutes. 950pl of room temperature SOC medium was then added to
the tubes which were incubated at 37 °C for 1.5 hours in a rotary incubator at 150 r.p.m.
lOOpl of these transfectant cultures were plated onto duplicate LB agar plates
previously supplemented with 50pgml-l of ampicillin and 40pl each of lOOmM IPTG
and 40mg/ml X-Gal. Once the culture liquid had absorbed, the plates were inverted and
incubated for 24-48 hours at 37 °C after which they were shifted to 4 °C for 2 hours to
allow for proper colour development.
Luria-Bertani medium: 1% Bacto-Tryptone
0.5% Bacto-Yeast extract
0.17M NaCl, pH 7.0





20mM glucose, filter-sterilized, pH 7.0
LB/amp/IPTP/X-Gal plates: To 1L of LB add 15g agar, cool to 50 °C, add
ampicillin to 50pgml l, IPTG to 0.5mM and X-Gal to 80pgmr'(or add as above)
and pour.
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Isolation of recombinant plasmid DNA
Transformants were screened with mini-preps and restriction analysis. Once
screened, maxi-preps and sequence analysis were performed. All cultures were
supplemented with ampicillin to maintain the selection of transformed bacteria. The
alkaline cell lysis technique is a modification of that described by Maniatis et al (1989;
1.38-1.39).
The mini-prep protocol is a modification of the method adopted by Birnboim and
Doly (1979). A single white colony was inoculated into 5ml of ampicillin-supplemented
LB medium in a sterile 15ml Falcon tube using a sterile loop. This was incubated
overnight at 37 °C in a rotary incubator at 225 r.p.m. A satisfactory bloom should
achieve an OD 600 of ~600. 1.5 ml of this culture was then pelleted in a centrifuge at
12,000xg with the remaining culture stored at 4°C. The bacterial pellet was then
resuspended in lOOpl of ice-cold GTE and lysed with 200pl of freshly prepared 0.2M
NaOH, 1% SDS with a 5 minute incubation on ice. This lysate was then neutralised with
150pl of ice-cold 5M potassium acetate solution. The resulting flocculate was then
centrifuged at 12,000xg for 5minutes and the clear supernatant then taken and treated
with 0.5pl of lOOpgpl-1 DNase-free RNase A by incubating for 5minutes at room
temperature. DNA was then extracted with an equal volume of
phenol:chloroform:isoamyl alcohol (25:24:1) with a lminute vortex and a 5minute
12,000xg centrifugation. The upper aqueous phase was transferred to a fresh tube, an
equal volume of chloroform:isoamyl alcohol (24:1) added and the tube revortexed and
centrifuged. The DNA in this aqueous phase was precipitated with 2.5 volumes of ice-
cold 100% ethanol for 5minutes on dry ice. The DNA was pelleted by centrifugation,
rinsed with ice-cold 70% ethanol before repelleting and drying in a spinvac. The pellet











5M K acetate (60mls)
glacial acetic acid (11.5mls)
DEPC treated water (28.5mls)
Maxi-preps involved incubating to 15ml those transfectants selected from the
mini-prep run and restriction analysis. These cultures were further incubated in 500ml of
LB medium with ampicillin in 2L flasks overnight at 225 r.p.m in an incubator-shaker.
Satisfactory late-log-phase growths were harvested by pelleting the bacteria in 250ml
Nalgene polycarbonate centrifuge pots spun at 6000 r.p.m. and 4 °C for 5 minutes in a
Sorvall GSA rotor. As before, each pellet was resuspended in GTE (12mls) before lysing
in alkaline SDS (24mls) for 5 minutes and neutralising in 5M potassium acetate solution
(16mls) with all reactions on ice. After a 10 minute 6,000 r.p.m spin, the supernatants
were filtered through several layers of gauze into fresh pots then mixed with 0.6 volume
of isopropanol (32mls) and left at room temperature for 30 minutes. The mixed
precipitate was then pelleted by centrifugation at 10,000 r.p.m. for 3 minutes. This pellet
was then dried and resuspended in 2.2ml of Tris-EDTA buffer (lOmM Tris, ImM EDTA,
pH8.0).
Plasmid DNA was purified by Cs-gradient centrifugation. 2.7g of CsCl were
dissolved in the plasmid preparation (final concentration lgml-1) along with a lOOpl
aliquot of 10mgml-l ethidium bromide. This solution was then placed and sealed in a
Beckmann Quickseal tube and spun at 100,000 r.p.m for 4 hours at 22 °C in a Beckmann
Optima Ultracentrifuge TLX with a TLA 100-3 rotor. The lower band of plasmid DNA
was taken off and then rebanded as above.
Lollowing this, the ethidium bromide was removed by adding a 0.6 volume of
isopropanol and centrifuging the mixture at 1,500 r.p.m. for 3 minutes, to then recover
the lower aqueous phase containing the plasmid DNA. This was repeated until the pink
stain of ethidium bromide had been removed. The interface between aqueous and organic
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phases becomes laterally less distinct and the CsCl can precipitate out but these can be
remedied by adding a further 50pl of TE and performing a brief incubation at -20 °C.
The plasmid was then desalted by dialysing for 24 hours against 3 changes of 2L
Tris-EDTA buffer, pH 8.0, using Spectra-por molecular porous dialysis membrane with a
3,500dalton cut-off. The plasmid concentration was then determined by
spectrophotometry and the solution diluted to a working concentration of lpgjal"1 in Tris-
EDTA.
Restriction analysis
A restriction map was generated for the IGF-1R cDNA sequence 1063-1659
(Holyrood server). The plasmid mini-preps were cut with Eco RI to yield the insert which
was digested with Ava II (restriction site G*G(A/T)CC) according to the protocol
outlined in Sambrook and Maniatis (1989).
1GF-1R (Ava II): insert restriction site 1348
(1063-1659) insert product size 311 + 285 base pairs
Restriction digest: lpg of plasmid DNA
lp.1 of Eco RI (lOu p.1-1)
lpl of Ava II (lOu (0.1-1)
2|ol of 10X Buffer C (lOmM Tris-HCl, lOmM MgC12,
50mM NaCl, ImM DTT, pH7.9 )
nuclease-free water to a total volume of 20pl
The reactions were run at 37 °C for 1 hour before adding 3pl of loading buffer and
analysing by electrophoresis on a 2% agarose gel.
Sequence analysis
Selected transformants were insert-sequenced using an adaptation of the
dideoxynucleotide chain termination method of Sanger (1977). Thermo Sequenase
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radiolabeled terminator cycle sequencing was employed (Amersham Pharmacia Biotech
Inc, Ohio) with resolution on urea-acrylamide gels.
Termination mixes were initially prepared by adding 2pl of dGTP nucleotide
master mix (7.5mM of dATP, dCTP, dGTP, dTTP) to 0.5pl aliquots of
[a-33P|ddNTP(G,A,T or C)(Redivue, 450mCiml"'). Reaction mixes were then prepared as
below:
Reaction mix : 2pl of reaction buffer (260mM Tris-HCl, pH 9.5, 65mM MgCl2)
500ng of plasmid-insert DNA
2pmol of primer - Ml3 forward primer
(5' -GTTTTCCCAGTCACGACGTTGTA-3')
nuclease-free water to a total volume of 20pl
2pl of thermo sequenase polymerase (4u pi"1) (add last)
4.5pl of the above reaction mix were added to each 2.5pl termination mix aliquot and
were then placed in a PCR reactor sub-ambient at 4 °C then run on the following
program:
Melt: 95 °C for 30 seconds
Anneal : 55 °C for 30 seconds
Extend : 72 °C for 60 seconds
Cycles: X30
4pl of stop solution (95% formamide, 20mM EDTA, 0.05% bromophenol blue, 0.05%
xylene cyanol) were then added to the above reactions and the samples heated to 70 °C
for 2 minutes before loading onto a sequencing gel:
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sequencing gel: lOmls of 10X TBE buffer
(lOOmls, 6%) 15mls of 40% acrylamide/bis-acrylamide
42g of urea
600pl of 10% ammonium persulphate
40pl ofTEMED
water to a total volume of lOOmls
10XTBE: 108g Tris base
55g Boric acid
9.3g Na2EDTA.2H20
water to a total volume of 1L
The gel was prepared and mounted on the electrophoresis apparatus (Biorad), the
chambers filled with IX TBE, the water-cooling jacket turned on and the gel pre-run for
30minutes. 3pl aliquots of the samples were then double loaded (ie TCGATCGA) and
run at 2kV for approximately 3 hours until the dye-front had migrated about one half the
length of the gel whereupon the gel was reloaded and run for a further 3 hours to read
more distally. The apparatus was then carefully disassembled and the gel soaked in 5%
acetic acid, 15% methanol for 15 minutes then dried on Whatman paper at 80 °C for 2
hours in a gel drier on vacuum. The gel was then exposed for 48 hours using Kodak
Biomax MR film. This was developed in an RP X-Omat automated developer and the
sequence read.
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The sequenced plasmid~IGF-lR insert read thus :
Plasmid:
2994' TGAATT GTAATACGAC TCACTATA
1' GGGCGAATTG GGCCGACGTC GCATGCTCCC GGCCGCCATC
GCGGGAATTC GATT
Insert (sequence match for IGF-1R exon 4-8 cDNA):
1063 ACCATTGA TTCTGTTACT TCTGCTCAGA TGCTCCAAGG
1101 ATGCACCATC TTCAAGGGCA ATTTGCTCAT TAACATCCGA
1141 CGGGGGAATA ACATTGCTTC AGAGCTGGAG AACTTCATGG
1181 GGCTCATCGA GGTGGTGACG GGCTACGTGA AGATCCGCCA
1221 TTCTCATGCC TTGGTCTCCT TGTCCTTCCT AAAAAACCTT
1261 CGCCTCATCC TAGGAGAGGA GCAGCTAGAA GGGAATTACT
1301 CCTTCTACGT CCTCGACAAC CAGAACTTGC AGCAACTGTG
1341 GGACTGGGAC CACCGCAACC TGACCATCAA AGCAGGGAAA
1381 ATGTACTTTG CTTTCAA....
This orientated the insert to the plasmid's SP6 promoter for anti-sense transcription. As a
preliminary to this, the plasmid was linearised with Nco I (having first excluded a similar
restriction site in the insert) and it was then gel purified.
Sourcing of other riboprobes
Wilms' tumour suppressor
A 243bp insert spanning exonl and exon2 of WT-1 in pGEM3Z was a kind gift
from David Housman, MIT. This was restriction and sequence analysed prior to
linearising with Hind III and transcribing with T7 polymerase.
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C-myc and |3-actin
Linearised plasmid templates containing c-myc and (3-actin cDNA inserts
orientated downstream of SP6 and T7 promoters were obtained commercially (Ambion
Inc, AMS Biotech., UK ). The c-myc transcript encodes nucleotides 1197-1446,
Accession V00568, a 250 bp sequence spanning exons 2 and 3. The |3-actin transcript
encodes nucleotides 704-947, Accession X00351, a 245bp sequence.
2.7. RNA analysis - Northern blotting
Gel electrophoresis
The analysis of total RNA by denaturing formaldehyde gel electrophoresis with
Northern transfer and riboprobe detection is an adaptation of that previously described by
Maniatis ( 1989 ), optimised for high molecular weight transcripts and low copy
numbers.
A 1% gel was prepared by melting 0.75g of Agarose NA ( Pharmacia Biotech
Ltd, Milton Keynes) in 54ml DEPC treated water. This was allowed to cool to 55 °C
before adding lpl of lOmg/ml ethidium bromide and 7.5ml of MOPS 5X buffer and
13.5ml of 37% formaldehyde (12.3M, pH>4.0).





A 5mm gel was poured into a sealed midi-gel tray with a 1.5mm comb (Northumbria
Biologicals Ltd. ) having previously cleaned the gel apparatus in weak detergent, 3%
hydrogen peroxide and DEPC-treated water.
20pg total RNA samples suspended in 5pl nuclease-free water were mixed with
lOpl RNA sample buffer and heated at 65 °C for 5 minutes before cooling on ice and
adding 2pl of RNA loading buffer.
60
RNA sample buffer: 10ml deionized formamide
3.5ml 37% formaldehyde
2.0ml MOPS 5X buffer
RNA loading buffer: 50% glycerol
ImM EDTA
0.4% bromophenenol blue
The gel tray was was placed in the electrophoresis apparatus and covered to a 1cm
depth with 1L of MOPS XI before pre-running for 10 minutes. The RNA samples were
then loaded alongside 5pl of ssRNA ladder ( Millennium markers, Ambion, UK) and run
at 80V (5V/cm ) at 4 °C for 3 hours until the bromophenol blue had migrated to the
bottom of the gel. The gel could then be examined and photographed under UV
transillumination.
Northern transfer
An adaptation of Chomczynski's downward alkaline blot technique was
employed ( Chomczynski, 1992 ) where the formaldehyde gel was capillary blotted to
positively charged nylon filters ( BrightStar-Plus, Ambion ) under alkaline / 20X SSC
elution.
The gel was briefly soaked in DEPC-treated water to remove the formaldehyde
before soaking in 0.05N sodium hydroxide for 20 minutes to partially hydrolyse the
RNA and aid high molecular weight transfer. The gel was then soaked in 20X SSC for 45
minutes whilst the transfer stack was prepared.
20X SSC: 3M sodium chloride.
0.3M tri-sodium citrate, pH 7.0.
A 5cm stack of paper towels was surmounted by 3 dry pieces of Whatman 3MM filter
paper and on top of this were added 2 more pieces of 3MM filter paper trimmed to the
size of the gel and pre-wetted in transfer buffer ( 20X SSC, 0.05N NaOH ). The nylon
membrane, trimmed to size, was briefly wetted in transfer buffer and placed atop the
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filter sheets. The gel was then aligned bottom side up upon the membrane and in turn
surmounted by 3 further transfer buffer soaked 3MM filter papers and a sufficient length
of wetted 3MM filter paper leading to the buffer reservoir. The gel and apparatus were
surrounded by Saran wrap and the whole stack weighted with 150g. Capillary alkaline
blotting proceeded for 2 hours at room temperature after which the apparatus was
carefully disassembled and transfer confirmed by UV transillumination. The
hybridisation filter was then soaked in 5X SSC for 5 minutes, dried at room temperature
before cross-linking by baking in a vacuum oven at 80 °C for one hour.
In vitro transcription and riboprobe hybridisation
Formamide-based hybridisations were performed using riboprobes generated with
modified nucleotides ( Strip-EZTM RNA, Ambion, UK) to allow effective resolution at
sequential rehybridisation with probes for IGF-1R, c-myc (pTRI-c-myc-human,
Ambion), WT-1 and |3-actin (pTRI-Actin-human, Ambion, UK).
The filters were initially prehybridised in 10ml of preheated hybridisation solution
per 100cm2 of membrane in a Hybritube 15 ( Gibco BRL ) in a rotary hybridisation oven
at 65 °C for 4 hours.
6.25ml formamide
3.125ml 20X SSPE
0.5ml 50X Denhardt's reagent
0.125ml 10% SDS
2.5ml DEPC-treated water
0.125ml denatured salmon testes DNA
( lOmgml ')
20X SSPE : 3M NaCl
0.23M Monosodium phosphate ( NaH2PC)4)
25mM EDTA, pH 7.4




50X Denhardt's : 1% Ficoll
1% polyvinylpyrrolidone
1% bovine serum albumin
( 0.2 fxm filtered )
In vitro transcriptions used an adaptation of the original technique described by
Melton and Maniatis (1984) employing a modified CTP nucleotide (Ambion) to generate
|a-32P|-labelled riboprobes according to the following protocol:
reaction mix : nuclease-free water to 20pl
0.1 [xg of linearised plasmid template
2pl of 10X transcription buffer
lplof lOmM ATP
1 p,l of 2mM modified CTP
lplof lOmM GTP
0.5[il of lOmM UTP
5pM of [a-32P]-UTP (Redivue, 450Cimmol-l)
2pl of SP6 or T7 RNA polymerase depending on
insert orientation
The reaction was allowed to proceed for 1 hour at 37 °C before adding lpl of DNasel and
incubating for a further 15minutes at 37 °C.
Unincorporated nucleotides were removed by filtration through a Sephadex G-50
column (Pharmacia Biotech, Milton Keynes). RNase-free G-50 columns were
equilibrated with 3ml of RNase-free buffer containing lOmM Tris-HCl, pH 7.5 with
ImM EDTA. The transcription product was then added to the gel bed and a further 400p,l
of buffer added. The purified product was then eluted with a further 400pl of buffer.
The purified radio-labelled RNA probe was heat denatured at 90°C for 10 minutes
before adding directly to the hybridisation fluid. Hybridisation proceeded for 18 hours at
65 °C after which the filter was removed and washed sequentially in increasingly
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stringent washing buffer as detailed below whilst monitoring with a handheld counter
and a digital scintillation imager.
1. Wash twice with 2X SSC, 0.1% SDS (20ml per 100cm2) for 10 minutes at
room temperature.
2. Wash twice with 0.2X SSC, 0.1% SDS (40ml per 100 cm2) for 15 minutes at
65 °C.
3. Wash twice with 0. IX SSC, 0.1% SDS (40ml per 100 cm2) for 15 minutes at
65 °C.
The filter was then rinsed in 0.1X SSC, wrapped in Saran wrap and imaged either
with the scintillation imager or by exposing Hyperfilm TM-MP film in a Fastrad
Autoradiography cassette with an intensifying screen at -70 °C. After a 12-48 hour
exposure the film was developed in an RP X-Omat automated developer. Densitometry
readings of the films were performed with the aid of an optical densitometer (Northern
Light, Canada).
Stripping and reprobing blots
After exposure, the filters were stripped in probe degradation buffer
(Ambion,UK) with 0.1%SDS using 10ml/100cm2 of membrane at 68 °C for 10 minutes
before incubating in 10ml/100cm2 blot reconstitution buffer (Ambion, UK) again at 68 °C
for 10 minutes. The filter was then reimaged and if there remained a high residual signal
which was anticipated to interfere with subsequent imaging, the filter was restripped for
15 minutes in 500ml of boiling 0.05X SSC and 0.01 M EDTA, pH 8 with 0.1% SDS
added when off the boil. The filter was then rinsed in 0.01X SSC before a further
exposure and reprobing.
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2.8. Protein analysis - Radioligand binding
Membrane microsome preparation
Microsomal preparation from the membrane fraction was an adaptation of the
technique of Kuo et al., 1990. Freshly micro dissected normal and tumoural epithelium
were minced in lysis buffer with a Brinkman polytron on ice.
Lysis buffer : 0.25M sucrose, 0.15M NaCl, 25mM Tris-HCl,
(1 g tissue/10ml) 1 % Triton-X, 0.05% Sodium deoxycholate,
ImM EDTA, ImM PMSF, ImM NaF, lpg/ml aprotinin,
lpg /ml pepstatin, lpg/ml leupeptin, ImM NaF4 and
ImM Na3V04, PH7.4at4°C
The remaining non-homogenised tissue and nuclear debris were then removed by
centrifuging at 3000 r.p.m. for 30 minutes at 4 °C. The supernatant was then carefully
removed and the nuclear and mitochondrial fraction were then pelleted by centrfuge at
13,000g for 30 minutes at 4 °C. The resulting supernatant was then ultracentrifuged at
100,000g (40,000 r.p.m in a Sorvall OTD-65 Ultracentrifuge) for 60 minutes at 4°C to
pellet the memrane and remaining high molecular weight fraction. This pellet was then
suspended in binding buffer with a Dounce homogeniser and the protein concentration
measured (Bradford assay). In each membrane preparation the specimens were treated
identically and were homogenised for the same period of time.
Binding buffer : 25 mM TrisHCl, 0.9% NaCl, 10 mM MgCl2,
2.5 mM EDTA, 0.1% BSA, 10 4 M PMSF,
pH 7.6 at 4°C
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Radioligand competitive binding assay
Reactions were carried out in triplicate in 75mm plastic tubes which had been
precoated with 0.1% BSA. 400pg aliquots of membrane microsome in 400pl binding
buffer were incubated for 16 hours at 4°C with 0.05mCi of 125I-1GF-1 (Amersham, UK)
at a total concentration of 2nM and with or without the addition of unlabelled IGF-1 at
varying concentrations (0.1 to 10 nM). Reactions were stopped by the addition of 3 ml
ice cold binding buffer, the membranes pelleted by centrifugation at 36,000g for 30
minutes then resuspended and washed with a further 3 ml of binding buffer.The bound
radioactivity in the subsequent microsome pellet was measured in a Beckman gamma
counter.
2.9. Protein analysis - Immunocytochemistry
Tissue specimens for immunocytochemistry were taken from tumour margins to
include both normal and tumoural mucosa. Both frozen sections and paraffin embedded
specimens were found to be suitable for IGF-1R analysis, but paraffin embedded ACFs
and tissue controls were more widely available in archival stores and so, for uniformity,
this method was adopted and is described herein. Briefly, specimens were fixed in PBS-
buffered 4% formaldehyde for 2 to 4 hours and then serially dehydrated by soaking for 1
hour in increasing concentrations of ethanol. After soaking in 100% ethanol, the
specimens were soaked in 2X changes of xylene for 1 hour each before embedding in
paraffin by routine processing with a Bayer VIP processor. The hardened wax blocks
were then trimmed for sectioning. 4pm sections were cut on a bench-top microtome and
mounted on Superfrost plus slides ( Merck) before drying for several hours at 50 °C in an
oven.
Freshly cut specimens were chosen that would allow assessment of normal and
tumoural tissue in the same field at histological examination. Dewaxing and rehydration
of the selected paraffin-embedded specimen slides in preparation for
immunocytochemistry involved a 1 hour incubation at 60 °C followed by 2X 3minute
washes in xylene. The slides were then serially rehydrated with 2X 3minute washes in
66
100%, 95%, 70% and 30% ethanol followed by 10% PBS then TBS and then finally
distilled water.
PBS 1 tablet of Dulbeccos A added to lOOmls distilled water
TBS For 1L :6.05g of Trizma base was added to 80mls of distilled water
then 3.3mls of concentrated HC1 were added. This solution was
added to 8.2g of NaCl dissolved in 920mls distilled water. To this
was added 1ml of Triton X 100 dissolved in 5mls of warm distilled
water. pH 7.6. Stored at 4°C.
Antigen retrieval was aided by microwaving the sections for 2X 5 minute cycles
at 800 watts in 0.01M sodium citrate, pH6.0, before allowing the sections to stand for 20
minutes in the hot acid. The slides were then washed for 5 minutes in TBS.
Immunodetection employed a chicken polyclonal IgY primary antibody to the
human IGF1-R a-subunit ( Upstate biotechnology, Lake Placid ). This had been
produced with a synthetic immunogen [CKYADGTIDIEEVTENPKT ] corresponding to
residues 642-659 of the a-subunit (Rosenzweig, 1990) with subsequent PEG and
ammonium sulphate purification of the IgY. This primary polyclonal was detected with a
biotinylated rabbit anti-chicken antibody (Zymed, San Francisco) which in turn was
detected using the streptavadin-horseradish peroxidase technique.
The hydrated antigen-unmasked slides initially had their endogenous peroxidase
activity blocked by incubating in 3% hydrogen peroxide in distilled water for 15 minutes.
The slides were then washed twice in distilled water then TBS, each for 5 minutes. Non¬
specific binding was then blocked with a 20 minute incubation in 10% rabbit non¬
immune serum in TBS with 2% bovine serum albumin at room temperature. The serum
was then carefully drained from the slides and the specimens ringed with a wax PAP
marker pen. The slides were then incubated with 200pJ aliquots of lOpgml1 anti-IGF-lR
a-subunit polyclonal for 1 hour at room temperature, the optimal conditions having been
previously determined by time-dilution experiments. Following this, the slides were
washed twice with TBS for 5 minutes. Detection was performed by incubating with
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200^1 of 1:400 biotinylated rabbit anti-chicken antibody in TBS for 30 minutes. Two
further 5 minute washes in TBS were followed by a 30 minute incubation with freshly
prepared Streptavadin-horseradish peroxidase complex (Vector Laboratories,
Peterborough). The slides were again washed twice in TBS for 5 minutes before
developing in 0.06% 3,3'-diaminobenzidine tetrahydrochloride (Sigma, UK) for less than
10 minutes. Following washing in TBS then water, the slides were counter-stained in
Mayer's haematoxylin and 0.3% ammonia water before dehydrating in increasing
concentrations of ethanol. The slides were finally washed in xylene then mounted with
DPX and a coverslip.
Tissue and reagent controls were run synchronously in the above protocol.
Hepatocytes are known to express low levels of the IGF-1R ( Lemmey, A.B., 1997)
whilst renal tubular epithelial cells express high levels of the IGF-1R (Pillion, D.J., 1988)
and so paraffin-embedded sections from normal liver and kidney were used as tissue
negative and positive controls respectively. Reagent negative controls were prepared by
peptide-absorbing the primary antibody with the original immunogenic synthetic peptide
corresponding to residues 642 to 659 of the human IGF-1R a-subunit that was used
initially as the inoculant in the production of this polyclonal (Upstate Biotechnology ).
Briefly, the lyophilised a-subunit peptide was rehydrated and serially diluted in TBS to a
concentration of 0.2 mgml-1 before storing at -20 °C. Peptide absorption was performed
by incubating the primary antibody with a tenfold excess by weight of the synthetic
peptide for 2 hours at room temperature. The resulting immune complexes were then
removed by centrifugation at 13,000 Xg for 15 minutes and the supernatant taken and
used for the reagent negative primary incubations in the above protocol.
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2.10. Protein analysis - Primary cultures and immunocytochemistry
Primary cultures
The technique employed for the primary culture of colonic carcinomas and
normal epithelial explants was adapted from that of Paraskeva et al., (1996). The
specimens were also examined histologically with IGF-1R immunohistochemistry at the
time of primary culture.
Microdissected mucosa was transported in washing medium at 4 °C and then
stringently washed before transferring to and processing aseptically in a laminar flow
hood (Microbiological Class II, Howarth Air Engineering Ltd., Farnworth, UK). The
specimens were diced with a scalpel to less than 1mm3 and further stringently washed by
pipetting.
Washing medium : RPMI 1640 medium, 5 % fetal calf serum (FCS),
2mM glutamine, 200 U/ml penicillin,
200 pg/ml streptomycin and 50pg/ml gentamicin
The tissue pieces were then suspended in wash medium (500mg in 8ml) to which
hyaluronidase at lOOU/ml (Sigma) and collagenase at 240U/ml (Sigma) working
concentrations were added. The tissues were digested for 12 hours at 37°C in a rotary
incubator before centrifuging at 1600g for 3 minutes. The retrieved organoids were
washed. These in turn were then retrieved by a combination of gravity sedimentation and
differential centrifugation at 160g for 1 minute to aid the removal of fibroblasts. This was
repeated until the organoids were microscopically clear of fibrous material. The
organoids were then transferred into conditioned growth medium in collagen coated
75cm2 culture flasks in a humidified incubator (T305GF Assab ; Kebo Assab AB, Solna,
Sweden) in an atmosphere of 95% air and 5% C02 at 37°C.
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Growth medium : As wash medium with 10% FCS,
lmg/ml hydrocortisone succinate, 0.2 U/ml insulin.
Medium was conditioned for 24 hours on 3T3 cells (ATCC no. CCL92) then
dialysed and lyophilised to be reconstituted in an initial equivalence in growth medium.
75cm2 culture flasks were collagen coated by dissolving 50mg type VI human
collagen (Sigma) in 50ml 0.1% glacial acetic acid and using a film of this to coat the
bottom of the flask. This was then air dried for 4 hours and washed briefly in wash
medium before use.
Once a primary culture had been established, organoids were passaged by the
addition of 2.5 ml of 2u/ml Dispase (Boehringer Mannheim) in wash medium for 15 to
60 minutes. Once a cell line had been established, passaging was usually possible with
0.1% trypsin/ PBS. Prior to the immunohistochemistry studies, cells were tested for
growth on soft agar and cytokeratin staining.
Cell culture immunocytochemistry
Cell lines were plated down on collagen coated 24 well plates for at least 48
hours. Depending on the required degree of confluence or differentiation, the cells were
then washed in PBS and fixed in 200pl ice cold paraformaldehyde / acetic acid [4% / 2%]
in PBS with 200pl washing medium for 15 minutes. The cells were then washed twice in
PBS at room temperature for 15 minutes before their endogenous peroxidase activity was
blocked with 200pl of 3% hydrogen peroxide for 5 minutes. After a further wash in PBS,
non specific binding was blocked by a 20 minute incubation with 20% non immune
rabbit serum / 1% BSA in PBS at room temperature. The blocking solution was then
removed and the primary antibody incubation performed with 200pl of lOpg/ml anti-
IGF-1R a-subunit polyclonal in 1% BSA in PBS at 4°C for 12 hours. Control slides were
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incubated with the peptide absorbed antibody. Thereafter, the standard protocol from the
tissue histochemistry was followed - namely, detection with a biotinylated rabbit anti-
chicken antibody followed by Streptavadin / HRP then developing with DAB and
counterstaining with Haematoxylin and 0.3% ammonia water.
2.11. Protein analysis - Western blotting
The low IGF-1R expression in normal colonic tissue necessitated enrichment by
immunoprecipitation of the peptide as a prelude to SDS-PAGE and immunodetection.
This was adapted from the protocol described by Maniatis (1989).
Protein extraction and immunoprecipitation from snap frozen tissue
The susceptibility of the mature peptide to cleavage during mechanical disruption
of frozen tissue and from endogenous proteases required tissue specimens to be
homogenised in a Ystrall homogeniser on ice having been briefly thawed in a lysis buffer
containing protease inhibitors.
Lysis buffer : 0.25M sucrose, 0.15M NaCl, 25mM Tris-HCl,
(lg tissue/10ml) ImM EDTA, ImM PMSF, ImM NaF, lpg/ml aprotinin,
lp,g/ml pepstatin, lpg/ml leupeptin,
0.05% Sodium deoxycholate, ImM NaF4 and
ImM Na3V04, pH7.4at4°C
Remaining non-homogenised tissue and nuclear debris were then removed by
centrifuging at 3000 r.p.m. for 30 minutes at 4 °C. The supernatant was then carefully
removed and the membrane and high molecular weight fraction then pelleted from this by
ultracentrifugation at 30,000 r.p.m. for 40 minutes at 4 °C (Sorvall OTD-65
Ultracentrifuge). The pellet was resuspended in approximately 1ml of ice-cold lysis
buffer. To reduce non-specific binding during subsequent immuno-separation, this lysate
was precleared by incubating with 100pl of 50% Protein G Plus-Agarose slurry
71
(Oncogene Research Products, Cambridge) in PBS for 10 minutes at 4 °C. This was then
centrifuged at 13,000 Xg for 10 minutes at 4°C, the supernatant taken and its protein
content determined colourimetrically by Bradford assay.
Briefly, 80pl aliquots of the lysate diluted at least 1/10 in water were added to
20pl of Coomassie Plus reagent (Bio-rad) in a 96 well plate and read at 595nm on a
microplate reader (Bio-rad). This was read against a standard scale of BSA in water
prepared at concentrations ranging from 40pgml-l to lpgml-1.
The lysate was then diluted in PBS to a concentration of 10pgml-l. Separate
500pl aliquots of this lysate were then immunoprecipitated by incubating overnight at 4
°C on a rotary shaker with 5pg of the following antibodies :
anti-IGF-1R monoclonal antibody ( Oncogene Research Products,
catalogue no. GR11).
anti-IGF-1R polyclonal antibody (Upstate Biotechnology,
catalogue no.06-429).
The immunocomplexes were then captured by adding 100 pi of Protein G Plus-Agarose
and incubating overnight at 4°C. The chicken polyclonal incubation at this stage required
additionally a second-step antibody consisting of 5pg of rabbit anti-chicken antibody
(Upstate Biotechnology). The agarose beads were then collected by pulsing in a
microfuge for 5 seconds before washing 3 times with ice-cold PBS and collecting in a
similar manner. The agarose beads were then resuspended in 50pl of 2X Laemmli sample
buffer to dissociate the immune complexes. At this stage the samples could be stored at -
20 °C or boiled for 2 minutes and pulse spun to recover the supernatant ready for SDS-
PAGE.





(reducing gels prepared by the addition
of lOOmM dithiothreitol before use).
SDS-Polyacrylamide Gel Electrophoresis
SDS-PAGE was performed in a vertical electrophoresis apparatus with a
discontinuous buffer system (Protean II, Bio-Rad). The plates were assembled following
cleaning in detergent, distilled water and 100% alcohol. A 7.5% polyacrylamide
resolving gel was poured and allowed to polymerise for 20-30 minutes below a shallow
layer of isobutanol.
7.5% Polyacrylamide : 16.6ml of water (autoclaved)
Resolving Gel (30ml) 5.4ml of 40% acrylamide/bis-acrylamide
7.5ml of 1.5M Tris-base, pH 8.8
0.3ml of 10% SDS
0.3ml of 10% ammonium persulphate
12pl TEMED
The isobutanol was removed with a paper towel and the gel's top surface irrigated with
distilled water. A 5% stacking gel was then poured onto this surface around a 10 well
Teflon comb and allowed to polymerise for a further 20-30 minutes.
5% Polyacrylamide : 7.25ml of water
Stacking Gel (10ml): 1.275ml of 40% acrylamide/bis-acrylamide
1.25ml of 1M Tris-base, pH6.8
0.1ml of 10% SDS
0.1ml of 10% ammonium persulphate
lOpil of TEMED
Once polymerisation was complete, the comb was then removed and the top and bottom
gel surfaces irrigated with distilled water. The gel was then placed in the electrophoresis
apparatus and the top and bottom reservoirs charged with Tris-glycine buffer.
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Tris-glycine buffer (3L): 25mM Tris-base (9.09g)
250mM glycine (43.23g)
0.1% SDS (3g)
(distilled water to 3L)
The gel was now ready for loading. The protein samples were placed on ice after
boiling for 2 minutes, then loaded alongside 15pl of molecular weight markers, range 30-
200kdal ( Rainbow TM, Amersham). These markers had similarly been mixed 2:1 with
2X Laemmli sample buffer and boiled for 10 minutes prior to loading.
The electrodes were now connected to a Bio-rad power supply on a constant
current setting. The water jacket was turned on and the gel run at 20mA until the dye-
front had migrated to the interface between the resolving and the stacking gels. The gel
was then run at 40mA until the dye-front had migrated off the bottom of the gel. The
apparatus was carefully disassembled, ready for gel transfer.
Western blotting of protein to nitrocellulose filters
The SDS-poyacrylamide gel was trimmed and orientated then soaked in 1L of
transfer buffer for 30 minutes. During this time a nitrocellulose filter (Hybond C Extra)
and 4 pieces of Whatman 3MM paper were cut to the same dimensions as the gel and
soaked in transfer buffer.
Transfer buffer (1L): 48mM Tris-base (5.82g)
39mM glycine (2.93g)
0.037% SDS (3.75mls of 10%)
20% methanol (200ml)
distilled water to 1L, pH9.2.
Electroblotting was performed on a Transblot SD semi-dry transfer cell (Bio-
Rad). The electrodes were cleaned with 100% alcohol and 2 pieces of the transfer buffer-
soaked 3MM paper were placed on the anode and the nitrocellulose filter positioned atop
these. The gel was then briefly soaked in distilled water and then cajoled into position
above the filter using a small glass plate or domestic fish slice (Jenners!). The gel was
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orientated and aligned, taking care to avoid any air bubbles or short circuits. The 2 final
pieces of 3MM paper were aligned above the gel and the cathode placed on top of the
stack. The filter was electroblotted at 5V for 16 hours at room temperature. The apparatus
was then disassembled, the molecular weight marker lane removed and the filter's
orientation marked. Ponceau S staining at this stage showed some non-specific protein
carry-over but rarely revealed the specific bands arising from immunoprecipitation.
Blocking and antibody detection of the IGF-1R
The IGF-1R protein was detected using the anti-a-subunit polyclonal employed in
the immunocytochemistry protocol. This antibody was effective in detecting the IGF-1R
when either it or the monoclonal were used in the primary immunoprecipitation (both
antibodies recognise the a-subunit).
The filter was initially washed in 500mls of washing buffer for 10 minutes before
blocking in 0.1ml per cm2 of blocking solution for 1 hour.
Washing buffer : 24g of Tris-base
The filter was then transferred to a heat-seal bag where it was incubated with lp,gml-l of
anti-IGF-lR a-subunit IgY (Upstate Biotechnology) in 0.1ml per cm2 of blocking
solution overnight at 4°C on a rotary shaker. The filter was then washed twice in water
before incubating for 2 hours at room temperature with a 1:1000 dilution of secondary
antibody (a rabbit anti-chicken IgY linked to horseradish peroxidase, Upstate) in the
same volume of blocking solution as before. The filter was then washed twice with water,
then with wash buffer-0.05% Tween 20 for 5 minutes before soaking for 5 minutes each
in 5X changes of water. The membrane was then drained and its surface incubated for 1
minute with 0.125mls per cm2 of premixed ECL detection reagents (Amersham). After
Blocking solution :
(100ml)
(4L) 35.2g of NaCl
2.96g of EDTA, pH 7.5
5g of skimmed milk
2g of BSA
washing buffer to 100ml
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this, the membrane was drained of fluid, wrapped in Saran wrap and exposed for 1,2 and
4 minutes to HyperfilmTM-ECL. The film was then developed in an automated processor
and the bands examined both for their molecular weight and optical densitometry.
Pulse labelling and immunoprecipitation / SDS-PAGE
To further increase the sensitivity of Western blotting, primary cultures of colonic
cancers and normal epithelial explants were additionally pulse labelled with Met - 35S
(Amersham, UK) as a prelude to the immunoprecipitation and SDS-PAGE protocol
described above. Here, cell cultures were serum starved for 6 hours before culturing for
12 hours with Met deficient growth medium to which Met - 35S had been added.
Thereafter, the cells were lysed in the standard lysis buffer and immunoprecipatation and
SDS-PAGE proceeded as per the above protocol. Thereafter, the gel was transferred in
5% acetic acid, 15% methanol to Whatman paper in a gel drier on vacuum at 80 °C for 2




3.1. PCR mRNA analysis of normal and tumoural colonic mucosa
1GF-1R RNA analysis was initially performed by means of RT.PCR using mRNA
extracted from freshly dissected normal and tumoural tissue (2.2.2-2.2.3). The cycling,
annealing temperature and Mg concentrations were optimised for the reaction :
Primers : 5'-ACCATTGATTCTGTTACTTC-3'
5' -TTAAGAATGTCACAGAGTAT-3'
Product: 596 bp, 1063-1659 of IGF-1R cDNA sequence
(exon 4-8 of a-subunit)
PCR parameters : 40 x (60s @ 940C, 60s @ 520C, 120s @ 720C)
Tfl Taq polymerase
lpM primers and c50ng cDNA
[MgC^j = 1.5mM
Total RNA was initially assessed by RT.PCR without success. Subsequent mRNA
purification and RT.PCR yielded a weak signal for the 596 bp product for the IGF-1R
cDNA. Repeating the assay with total RNA once the PCR had been optimised similarly
failed to yield a product. Even with an excess of 2pg mRNA, a relatively low annealing
temperature and a high cycle number, the PCR had a low efficacy and yielded a low
product signal. In 3/14 reactions there was no detectable IGF-1R signal despite strong
HGPRT and IGF-1IR control signals. In those assays that yielded a product, normal
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mucosa gave a consistently weak or absent signal whilst cancers could yield strong or
absent signals.
Figure 3.1 PCR for IGF-1R and 1GF-2R (control) for normal and cancer mucosa.
596 bp IGF-1R PCR product weak / absent signal (arrowed) in normal mucosa (N) and
some cancer specimens (C) but stronger in some other cancer specimens (C). 720 bp
1GF-2R control present in normal mucosa(N) and cancer (C). RT negative controls (Cx)
using cancer specimens for 1GF-1R and 1GF-2R.
IGF-1R IGF-2R IGF-1R IGF-2R
lOObp N C C N C lOObp N C C N C Cx Cx
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Table 3.1 IGF-1R PCR product signal (2p,g mRNA analysed):
Absent Weak Strong
Normal mucosa 2/7 5/7
Polyp 2/2
Cancer 1/5 2/5 2/5
At this stage, a fresh tissue positive control such as kidney was not readily
available. The PCR results were reproduced but the continued inter-specimen variability
was suggestive of poor PCR efficacy. Rather than redesign the primers, it was elected to
clone and sequence the normal mucosal PCR product with a view to subsequent
protection assay or Northern analysis. This was reinforced by the publication of a
competitive PCR study which had failed to determine any IGF-1R expression difference
between normal and tumoural mucosa (Zenilman, M.E., 1997).
3.2. PCR product analysis from normal mucosal cDNA
Normal mucosal PCR products were TA cloned into the pGEM-TE vector,
screened by restriction analysis (Figure 3.2) and then cycle-sequenced (Figures 3.3, 3.4).
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Figure 3.2 Restriction analysis screening of plasmid inserts. Lanes 4 and 5 show Ava II
digests of different plasmid inserts with predicted products of 311 and 285 base pairs for
the correct insert (arrows). Lane 5 shows the correct insert. This piasmid would then be
maxiprepped and the insert cycle-sequenced. Lane 4 shows an incorrect insert and this
plasmid would be discarded. Controls are uncut plasmids (pi) and plasmids cut with
EcoRl.
IGF-1R IGF-2R
lOObp pi EcoRl Avail pi EcoRl Pstl
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Figure 3.3 Sequencing gel of IGF-1R insert
TCGATCGA TCGATCGA
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Figure 3.4 Insert sequence :
Plasmid:
2994' TGAA'IT GTAATACGAC TCACTATA
1* GGGCGAATTG GGCCGACGTC GCATGCTCCC GGCCGCCATC
GCGGGAATTC GATT
Insert (sequence match for IGF-1R exon 4-8 cDNA):
1063 ACCATTGA TTCTGTI ACT TCTGCTCAGA TGCTCCAAGG
1101 ATGCACCATC TTCAAGGGCA ATTTGCTCAT TAACATCCGA
1141 CGGGGGAATA ACATTGCTTC AGAGCTGGAG AACTTCATGG
1181 GGCTCATCGA GGTGGTGACG GGCTACGTGA AGATCCGCCA
1221 TTCTCATGCC TTGGTCTCCT TGTCCTTCCT AAAAAACCTT
1261 CGCCTCATCC TAGGAGAGGA GCAGCTAGAA GGGAATTACT
1301 CCTTCTACGT CCTCGAGAAC CAGAACTTGC AGCAACTGTG
1341 GGACTGGGAC CACCGCAACC TGACCATCAA AGCAGGGAAA
1381 ATGTACTTTG CTTTCAA....
Sequencing confirmed the PCR product as IGF-1R exon 4-8 cDNA orientated to
the SP6 promoter of pGEM-TE ready for linearising with Ncol (Figure 3.5) before anti-
sense transcription. C-myc and WT-1 inserts were similarly sequenced prior to linearising
and riboprobe transcription (Figure 3.6).
Figure 3.5 Figure 3.6
82
3.3. Northern analysis
Total RNA Northern blotting with riboprobe analysis was performed in the first
instance. This was optimised for the high molecular weight and low copy number of
IGF-1R transcripts as detailed (2.2.3.3.1). A pilot assay with total RNA aliquots of
between 5 to 20pg from normal and tumoural mucosa was run on a standard
formaldehyde gel with hybridisation of the 596 bp IGF-1R riboprobe proceeding for 24
hours at 650C. RNA integrity was confirmed at each stage. This primary assay
determined that a weak 1 lkb signal, which corresponded with the IGF-1R transcript
molecular weight, could in fact be detected by conventional Northern analysis using 20pg
aliquots of normal mucosal total RNA. Thereafter, with 20\ig aliquots of matched normal
and tumoural mucosa total RNA, the hybridisation times were reduced to 12 hours and
Strip-EZ product used to facilitate sequential rehybridisations with c-myc, WT-1 and (3-
actin riboprobes. Optical densitometry was then performed on the autorads to allow
normalising and comparison. Additionally, part of each specimen was histologically
examined and graded - normal mucosa (N), tubular adenoma (TA), tubulovillous
adenoma (TVA), well differentiated cancer (CWD), moderately differentiated cancer
(CMD) and poorly differentiated cancer (CPD).
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N TA TA N TVA CWD N CMD N CPD N CPD
p-actin
1.9K
N TA TA N TVA CWD H CMD N CPD N CPD
Ethidium stained filter
N = normal mucosa for each specimen; TA = tubular adenomas; TVA = tubulovillous adenomas;
CWD, CMD and CPD = well, moderately and poorly differentiated cancers
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TA N TA TVA N CWD N CMD
C-MYC
TA N TA TVA N CWD N CMD
3.6K
TA N TA TVA N CWD N CMD
P-actin
TA N TA TVA N CWD N CMD
Ethidium stained filter
WT-1
N = normal mucosa for each specimen; TA = tubular adenomas; TVA =
tubulovillous adenomas; CWD, CMD and CPD = well, moderately and
poorly differentiated cancers
85
Table 3.2. Optical densitometry of Northern blots with IGF-1R normalised to |3-actin
Values are expressed as optical densitometry units with a maximun (completely exposed /
darkest reading) of 200 and minimum (nonexposed / lightest reading) of 0 for each blot.
Means for normal (mN) and tumours (mc) and their standard deviations expressed at the
foot of each column.
Specimen
Fig. 3.7
p-actin IGF-1R Norm. IGF-1R WT-1 Norm WT-1 c-myc Norm
c-myc
N* 173 43 40 27 25 11 10
TA 186 156 133 33 28 23 20
TA 144 129 142 31 34 20 22
N 191 41 34 34 28 29 24
TVA 144 146 161 37 41 20 22
CWD 181 174 153 59 59 68 60
N 156 45 46 61 62 25 25
CMD 151 155 163 62 65 36 40
N 141 44 50 19 21 17 19
CPD 163 72 70 53 52 47 46
N 127 27 34 31 39 18 23











p-actin IGF-1R Norm. IGF-1R WT-1 Norm WT-1 c-myc Norm
c-myc
TA 115 39 37 28 27 20 19
N* 93 18 20 85 99.6 33 39
TA 103 47 50 25 26 21 22
TVA 126 29 25 38 32 31 27
N 141 23 18 30 23 23 18
CWD 108 65 64 79 80 74 75
N 92 19 23 37 44 20 24










Figure 3.9 Densitometry of Northern blot (Figure 3.7): High levels of IGF-1R RNA
expression occur in polyps and well and moderately differentiated cancers but not in
the poorly differentiated cancers examined here. ( 95% confidence intervals were
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Figure 3.10 Densitometry of Northern blot (Figure 3.7) : High IGF-1R expression
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Figure 3.11 Densitometry of Northern blot (Figure 3.8): Tumour IGF-1R over
expression preceeding any expression changes in c-myc and WT-1.















T i 1 -J1 mmTmm
j 1 . —i 1 1 1
















1 1 1 1 1 1 1













TA TA TVA CWD CMD
specimen
89
The IGF-1R / (3-actin normalised densitometry readings from the above Northern blots
were combined by assuming equivalences in normal mucosal densitometries and a mean
normal mucosal densitometry of integer 1.0. This gave the following values for normal
and tumoural populations which can also be represented in the scatter diagram below :
Table 3.3 Statistical analysis of Northern blots: pooled normalised IGF-1R densitometries
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Normal: mean IGF-1R =1.0
95% confidence interval = ± 0.29
Tumours: mean IGF-1R = 2.94
95% confidence interval = ± 2.08
The wide range in tumoural densitometries meant that there was some overlap in
the 95% confidence intervals for tumoural and normal mucosal specimens. However,
when the two poorly differentiated cancers which expressed low IGF-1R levels (lanes 10
and 12 -1.69 and 1.82 ) and a specimen with degraded RNA (lane 16 - 1.23 ) are
excluded, from the comparison, this results in :
Tumours: mean IGF-1R = 3.40
95% confidence interval = ± 1.54
The majority of tumoural specimens (excepting some poorly differentiated
cancers - see below) expressed significantly higher levels of the IGF-1R than normal
mucosal specimens (p<0.05). On average, tumoural IGF-1R densitometry was 3.5 times
that of normal mucosa.
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There was comparatively little inter-specimen variability for IGF-1R expression
for the majority of normal mucosal RNA specimens (mean 1.0, range 0.73 to 1.40, n=8).
High molecular weight RNA degradation accounted for much of the variance.
The normalised IGF-1R densitometry from matched tumoural specimens in
comparison had a much higher mean of 2.94 and wider range of 1.23 to 4.63, n=12.
Again, loss of high molecular weight RNA integrity in one specimen (TVA in Figure 3.8)
accounted for the low value of 1.23.
The histologic grading of the specimens revealed an interesting pattern when
ranked to IGF-1R expression. Although all polyps and most cancers expressed high IGF-
1R RNA levels, the poorly differentiated cancers examined displayed a lesser degree of
expression albeit at a higher level than normal mucosa. The poorly differentiated cancers
with lower levels of IGF-1R expression also exhibited a more invasive morphology and
had areas of necrosis in comparison to poorly differentiated cancers with higher levels of
IGF-1R expression.
This pattern of high IGF-1R RNA expression in adenomas and most cancers but
comparatively lower levels in some poorly differentiated cancers ran somewhat contrary
to the pattern envisaged from the reporter assays as discussed in the introduction. The
blots were therefore sequentially rehybridised for the IGF-1R trans-regulators c-myc and
WT-1.
C-myc expression was found to be higher in all the cancer specimens in keeping
with the reports from previous studies (Melhem, M.F.,1992). This result was unaltered
when normalised to P-actin. However, there was no correlation between c-myc
expression and that of the IGF-1R. In fact, some poorly differentiated cancers expressing
high levels of c-myc expressed the lowest 1GF-1R levels for tumoural specimens.
Moreover, high 1GF-1R expression preceded c-myc expression in all of the tubular and
tubulovillous adenomas examined. Normalising IGF-1R expression to that of c-myc
simply exaggerated the expression profile that was observed in most tumours.
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The blots were then examined for expression of the Wilms' tumour suppressor.
Although the WT-1 promoter has been found to be hypermethylated in some colorectal
cancers (Hiltunen, M.O., 1997), this study demonstrated no significant difference for
WT-1 expression between normal and tumoural specimens and certainly no correlation to
IGF-1R expression.
In summary, 1GF-1R RNA was expressed at high levels in colo-rectal adenoma
and cancer specimens in comparison to matched normal mucosa specimens (from the
same resected specimen). However, the poorly differentiated cancer specimens examined,
although they expressed IGF-1R RNA at levels higher than their matched normal
mucosa, they expressed IGF-1R RNA at levels lower than those moderately and well
differentiated cancers and polyps examined. This pattern of IGF-1R expression during
colo-rectal neoplasia does not seem to be explained by the observed expression profiles
of the trans acting c-myc and WT-1. Also, it is difficult to envisage that p53 mutation, a
comparatively late event in colo-rectal neoplasia (Rodrigues, N.R., 1990) could instead
account for the observed early expression of the 1GF-1R during the neoplastic process.
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3.4. Radioligand binding analysis
IGF-1R expression at the protein level was next analysed by way of radioligand
binding using tissue microsomal preparations of normal and cancer mucosae. However,
there were considerable variations noted in the IQo within and between the specimens.
The errors inherent in the microsomal preparation technique therefore precluded a
meaningful comparison between different tissues and the method was abandoned.
Table 3.4 Radioligand binding : competitive assay. 500ug aliquots of normal and cancer
microsomal preparations were incubated with 2nM 125I-IGF-1 with and without
increasing concentrations of unlabelled IGF-1 in triplicate to determine the mean specific
binding values below (non-specific binding was that which was not displaced by a 100












Figure 3.12 Radioligand binding competitive assay : demonstrating IGF-1 specific
binding but no detectable difference between normal and cancer microsomal
preparations.
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IGF-1R expression in the polyp-cancer sequence was examined at the protein
level by means of immunohistochemistry. Archival material was used as this allowed
analysis of a greater range of specimens including aberrant crypt foci. Each assay was
verified by tissue and reagent positive and negative controls. Liver and kidney specimens
were used as tissue negative and positive controls respectively. Non-regenerative adult
liver is known to express low levels of the IGF-1R whilst adult renal tubules are known
to express high levels of the IGF-1R (Werner, H.,1989) (Ojeda, J.L., 1997). Reagent
negative controls consisted of the antibody product pre-absorbed with a molar excess of
the IGF-1R peptide. Immunohistochemistry staining was graded by two observers from 0
(no staining - tissue negative) to 5 (strong staining - tissue positive). Specificity was
further confirmed with Western blotting (section 3.6).
3.5.1. Immunohistochemistry : controls
Preliminary assays were used to determine the sensitivity and specificity of
immunostaining of the anti-IGF-lR polyclonal for tissue positive (kidney) and tissue
negative (liver) controls and reagent-negative (peptide-absorbed) controls. The pattern of
immunostaining observed agreed closely with these controls - liver immunostaining was
absent (graded 0) and kidney immunostaining was strongly positive (graded 5) (Figure
3.11). Immunostaining occurred in both the membrane and cytoplasmic pools of the
tissue positive controls, a pattern in keeping with other growth factor receptors. The
reagent negative (peptide absorbed) controls showed no immunostaining of the tissue
positive (kidney) controls.
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Figure 3.13 Immunohistochemistry : controls
Liver, x40 (tissue -ve control) displaying Kidney, x40 (tissue +ve control) showing
Kidney (tissue +ve) at high power showing Kidney (tissue +ve) / reagent -ve peptide
absorbed showing no uptake of staintubule (T) not glomerular (G) staining
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3.5.2. Immunohistochemistry : Normal mucosa
IGF-1R immunostaining of the cells in the normal colonic crypt was found to
correlate with the cells' position in the crypt and consequently with their morphology.
The cells of the basal colonic crypt immunoexpressed high IGF-1R levels (graded 4/5) in
their cytoplasms and membranes whereas the cells of the mid and upper colonic crypt
immunoexpressed low IGF-1R levels (graded 0-2) in their cytoplasms and membranes
(Figure 3.14). The anatomy and cell morphology of the normal colonic crypt has been
described in detail previously (Reviewed- Potten, C., 1990). The basal crypt cells have
been characterised as proliferative stem cells whereas the mid and upper crypt cells have
been described as transit amplifying (proliferating) and terminally differentiated cells
respectively. The cells in these different crypt regions are all aligned on the basement
membrane with a pallisaded appearance but have differing morphologies (and differing
IGF-1R expressions). The basal crypt cells (with high IGF-1R levels) have a relatively
undifferentiated morphology and are partially polarised with nuclei that are aligned a
slight distance "off' the basal aspect of the cell membrane (Figure 3.14). In contrast, the
cells of the upper crypt (with low IGF-1R levels) are terminally differentiated (columnar,
goblet, endocrine and Paneth cells) and are fully polarised with nuclei that are aligned
"on" the basal aspect of the cell membrane. The cells of the mid crypt (transit amplifying
or proliferating cells) show intermediate degrees of differentiation and polarisation with
nuclei that are either "on" or "off' the basal membrane. These cells, regardless of their
degree of differentiation or nuclear polarisation, expressed low IGF-1R levels (graded 0-
2). The basal crypt stem cells therefore appeared unique in their expression of high 1GF-
1R levels in the normal colonic crypt. The observed pattern of reduced IGF-1R
expression as basal crypt cells migrate to the mid and upper crypts was seen in all of 12
normal mucosa specimens where the entire crypt was visible and in all of 55 normal
mucosa specimens where only the upper crypt was visible.
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Figure 3.14 1GF-IR immunostaining : the normal colonic crypt
Normal crypt (low power, x40) Normal crypt (high power, x200)
1GF-1R immunostaining (brown) of basal
crypt stem cells (S) but not transit (TA) or
differentiated (DE) cells
n^:-yp£
ntW JV n .*
Normal basal crypt in transverse section Normal control (peptide absorbed, x40)
(x200) Staining of stem cell component No stainining of base (ie IGF-IR specific)
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Figure 3.14 IGF-1R immunostaining : the normal colonic crypt
Normal crypt (high power, x200). Basal crypt stem cells (BC) immunoexpress high IGF-
1R levels (brown stain). They have an undifferentiated and partially polarised
morphology with nuclei positioned "off' the basal membrane. Transit amplifying cells
(TA) immunoexpress low IGF-1R levels (low levels of brown staining). They have a
more differentiated columnar epithelial morphology and are partially or fully polarised
with nuclei positioned "off' or "on" the basal membrane. Differentiated enterocytes (DE)










3.5.3. Immunohistochemistry : The aberrant crypt focus
The histologic features of aberrant crypt foci and their likely role as neoplastic
precursors have been described previously (McLellan EA, 1991). In this study all 5 of the
aberrant crypt foci examined were found to immunoexpress the IGF-1R at high levels
throughout the length of their crypt axes (Figure 3.15). This is in contrast to normal
colonic crypts where only the basal crypt stem cells exhibited IGF-1R immunostaining
with a sharper demarcation between basal and mid crypt regions. There was to a limited
degree a gradient in IGF-1R immunoexpression along the aberrant crypt axis with
slightly higher immunoexpression at the base (graded 4/5) versus the upper crypt regions
(graded 3/4). However, there was no obvious correlation between IGF-1R
immunoexpression and the degree of cellular differentiation in the ACF. That is,
differentiated cells in the upper ACF immunoexpressed similar IGF-1R levels to
undifferentiated cells in the upper ACF. All the cells in the ACF had a partially polarised
morphology (like those of the normal crypt basal region) and so the higher IGF-1R
immunoexpression might simply reflect the expansion in the zone of proliferation in the
ACF as documented in previous studies (McLellan EA, 1991).
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Figure 3.15 IGF-1R immunostaining : normal crypts and the aberrant crypt focus
Low power, x40.
High levels of IGF-1 R are noted in the ACF as opposed to the normal crypts.
101
Figure 3.15 1GF-IR immunostaining : normal crypts and the aberrant crypt focus
Normal crypt (high power, x200)
Basal crypt IGF-1 R expression
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Aberrant crypt focus (high power, x2(X))
IGF-1 R expression in entire crypt
• • * v. • •:*
Normal colonic crypts show IGF-1R immunostaining confined to the basal crypt region.
In comparison, aberrant crypt foci show IGF-1R immunostaining throughout the crypt
length albeit with a gradient in immunoexpression to a limited degree.
3.5.4. Immunohistochemistry : colonic polyps
Adenomatous polyps also immunoexpressed high IGF-1R levels. In agreement
with the Northern blots, all of the 12 tubular adenomas and all of the 11 tubulovillous
adenomas examined were found to immunoexpress high IGF-1R levels (graded 4/5). In
the normal mucosa that lay adjacent to these polyps, the normal basal crypt regions
immunoexpressed high IGF-IR levels whilst the normal mid and upper crypt regions
immunoexpressed low 1GF-1R levels. The adenomatous crypts (unlike the aberrant
crypts) showed no concentration gradient in IGF-IR immunostaining along the crypt
axis. However, like the aberrant crypt cells, the adenomatous crypt cells had a partially
polarised morphology. Also, there was uniform IGF-IR immunostaining within and
102
between adenomatous polyp specimens with no correlation in immunostaining levels to
histologic features such as the degree of cellular differentiation, cytoplasm content or
dysplasia.
In contrast to aberrant crypt foci and adenomatous polyps, simple hyperplastic
polyps did not express the IGF-1R in their mid and upper crypt regions but only in their
basal crypt regions in a pattern similar to that found in the normal crypt.
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Figure 3.16 IGF-1R immunostaining : adenomatous and hyperplastic polyps
Hyperplastic polyp (Hyp), tubular Tubular adenoma (TA) and
adenoma (TA) and normal mucosa normal mucosa
Low power, x40 Low power, x40
IGF-1 R stain in tubular adenoma only IGF-1 R stain in tubular adenoma
Tubular adenoma (TA) and normal Tubular adenoma and normal crypt peptide
crypt at high power, x200 showing high absorbed reagent -ve control
IGF-1R expression in adenomatous crypt
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Tubulovillous adenoma (TVA), x40 Tubulovillous adenoma peptide absorbed
Showing IGF-1R stain in TVA reagent-ve control showing no staining
3.5.5. Immunohistochemistry : colonic carcinomas
IGF-1R immunoexpression occurred at high levels in most but not all colonic
cancers where immunoexpression was found to correlate with specific cancer cell
morphologies. High levels of 1GF-1R immunoexpression (graded 4/5) were found in 6
out of 6 of the well differentiated cancers examined, 7 out of 7 of the moderately
differentiated cancers examined and 3 out of 8 of the poorly differentiated cancers
examined (Figures 3.17-23). 5 out 8 of the poorly differentiated cancers examined as well
as foci in well and moderately differentiated cancers showed lower levels of IGF-1R
immunoexpression (graded 0 to 2), and this was found to correlate with two specific
cancer cell morphologies:
1. Low levels of IGF-1R immunostaining were observed in highly polarised
epithelial-type cancer cells in areas showing morphological features suggestive of
epithelial-mesenchymal transformation. In the invasive foci of well and moderately
differentiated cancers, there was a transition zone between epithelial and mesenchymal
morphologies (suggesting epithelial mesenchymal transformation or EMT). This
transition zone contained discrete groups of four or more highly polarised epithelial-type
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cancer cells showing low levels of IGF-1R immunoexpression. These epithelial-type
cancer cells with low IGF-1R immunoexpression had highly polarised nuclei aligned
"on" the basal membrane in contrast to the majority of epithelial-type cancer cells with
high IGF-1R immunoexpression which had partially polarised nuclei aligned "off' the
basal membrane (Figures 3.21 and 3.23 ). Basally aligned nuclei were a feature of post¬
mitotic cells in the normal colonic crypt but in cancerous crypts such cells showed
mitotic features such as mitotic bodies. Also, and unlike programmed differentiation in
the normal colonic crypt, epithelial-type cancer cells showing basally aligned nuclei
appeared to be the precursors of and dedifferentiate into mesenchymal-type cancer cells.
This was suggested by the intermediate cancer cell morphologies which lay adjacent to
and between these polarised epithelial-type cancer cells and mesenchymal-type cancer
cells. Like the mesenchymal-type cells, if these intermediate cell types immunoexpressed
low IGF-1R levels they had a disordered morphology with loss of cell-cell contact
whereas if they immunoexpressed high IGF-1R levels they had a more ordered
morphology with maintained cell-cell contact (see below).
2. Low levels of IGF-1R immunostaining were observed in mesenchymal-type
cancer cells with the loss of cell-cell adhesion. In the invasive foci of well, moderately
and poorly differentiated cancers (in 5 out of 8 of the poorly differentiated cancers which
had a mostly invasive morphology), the cancer cells showed low levels of IGF-1R
immunoexpression (graded 1 to 2). This reduction in IGF-1R immunoexpression was
observed in invasive mesenchymal-type cancer cells that had lost cell-basement
membrane or cell-cell adhesion (Figures 3.18-23). In contrast, adjacent mesenchymal-
type cancer cells that maintained cell-basement membrane or cell-cell adhesion
maintained high levels of IGF-1R immunoexpression (graded 4 to 5). The mesenchymal-
type cells that had lost cell-cell adhesion (and IGF-1R expression) had a higher rate of
cell necrosis but were otherwise morphologically similar to the mesenchymal-type cells
that maintained cell-cell adhesion (and IGF-1R expression). That is, there were no other
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morphologic differences in terms of nuclear pleomorphism, heterochromatin, multiple
nucleoli or mitotic bodies between these two cell groups.
Interestingly, a repeating pattern of cell morphology and IGF-1R expression was
observed in these cell types at foci which showed the morphological features of EMT and
invasion. Discrete groups of four or more mesenchymal-type cancer cells showing cell-
cell adhesion and high IGF-1R immunoexpression alternated with adjacent groups of four
or more mesenchymal-type cancer cells showing loss of cell-cell adhesion and low IGF-
1R expression. This occurred in a cyclical pattern at the invasive foci of cancer
specimens. A similar cyclical pattern was observed for epithelial type cancer cells
showing basal nucleus polarity. These cyclical patterns in IGF-1R expression suggest that
IGF-1R expression can be cell cycle dependent in these unique instances. Notably, this
pattern did not occur for other cell types in other specimens. In turn, this cyclical pattern
of expression suggests that IGF-1R expression is controlled in part by chromatin
remodelling (see discussion).
Although cancer cells immunoexpressed low IGF-1R levels during invasion,
established metastases (in lymph nodes or in liver) expressed IGF-1R levels in
accordance with their morphology (ie they expressed high IGF-1R levels unless showing
a highly polarised morphology or loss of cell-cell adhesion). Mesenchymal-epithelial
transformation was not seen in the specimens of metastases examined but was discerned
in small foci adjacent to areas of EMT in primary cancers where IGF-1R expression was
again in accordance with cell morphology.
Uniform immunostaining was observed in all specimens, again in accordance
with cell morphology. The above immunostaining findings were verified by internal
controls (adjacent normal crypts, both basal and upper crypt regions), by reagent negative
controls (peptide absorbed), and by tissue positive and negative controls as before
(Figures 3.17-23). Importantly, the immunohistochemistry findings are in agreement with
107
those of the Nothern analyses where poorly differentiated cancers with a predominantly
invasive morphology showed lower levels of IGF-1 R immunoexpression.
Figure 3.17 IGF-1 R immunostaining : cancer / well differentiated
Well differentiated cancer showing
IGF-1 R staining in cancer crypt but not
normal crypt. High power, x 200
~v;'3 *,.-*• ;
j ¥ i "
Normal ' Cancer crypt
crypt * , . . ■ ,
I ■ *
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-
~ ** "" V~
Well differentiated cancer (CWD) peptide
absosrbed control.
High power, x 200
N CWD
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Moderately differentiated (C) and Peptide absorbed control of moderately
normal (N) crypt. High power, x 200 differentiated cancer. High power, x 200
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Figure 3.18 IGF-1 R immunostaining : cancer / moderately differentiated
Moderately differentiated cancer and normal High power, x 200
Lymph node metastasis from the above Peptide absorbed control
Specimen. Low power, x 40





Figure 3.19a IGF-IR immunostaining : cancer / moderately and poorly differentiated.
High power, x 200.
The poorly differentiated (CPD) part of the specimen shows low IGF-IR levels and a
disordered and invasive morphology. In comparison, the moderately differentiated
(CMD) part of the specimen shows high IGF-IR expression and a more ordered "picket
fence" morphology with cells aligned on a basement membrane. Apoptotic bodies are
arrowed in the CPD part of the specimen but can be seen in both areas where the cells
have a more disordered morphology.
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Figure 3.19b IGF-1R immunostaining : normal mucosa and poorly differentiated cancer
High power, x 200.
Poorly differentiated cancer (CPD) showing reduced IGF-1R immunoexpression where
cells loose their cell-cell adhesion and have a more disordered morphology (b) in
comparison to cells showing high IGF-IR immunoexpression where they maintain cell-
cell adhesion and have a more ordered morphology (a). The normal upper crypt shows
low levels of IGF-1R immunostaining.
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Figure 3.20 IGF-1R immunostaining : cancer differentiation and necrosis, x 100
The above specimen is predominantly a moderately differentiated cancer (CMD) but with
areas of poorly differentiated cancer (CPD) and adjacent normal mucosa (N) containing
the basal crypt stem cell region (S). There are clear differences in IGF-1R expression
according to histologic type and cell morphology. High 1GF-1R levels (graded 4,5) are
expressed in the moderately differentiated cancer (CMD) and low levels (graded 1/2) are
expressed in the poorly differentiated cancer (CPD) which is noted to have an invasive
and disordered morphology with areas of necrosis (Nec). The crypts labelled "N" are
from the upper differentiated parts of normal colonic crypts. Their cells display normal
secretory glandular differentiation and have no significant IGF-1R expression. The crypt
labelled "S" represents the lower stem cell containing part of normal crypt. The cells can
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be seen to express a high level of the 1GF-IR which is reduced upon differentiation to
transit amplifying and differentiated enterocytes in the upper crypt (N).
Figure 3.21 1GF-IR immunostaining : variation in morphology and invasion. High
power, x 200
The above slide shows areas with a moderately differentiated cancer with glandular
organisation (A), a poorly differentiated cancer with cell-cell contact and a degree of
glandular organisation (B) and an invasive poorly differentiated cancer with loss of cell-
cell contact and no glandular organisation (CPD). Gland A has a more differentiated and
organised morphology with the cells forming a recognisable crypt. However, the cells in
this gland show differing morphologies and differing IGF-1R expressions. They show
several stages in the transition to basal nucleus polarity in epithelial type cells (1 to 3) and
a more invasive morphology in mesenchymal type cells (4 and 5) with concomitant
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reductions in their IGF-1R expressions. Partially polarised cells with nuclei "off' the
basal cytoplasm and a "picket fence" epithelial morphology can be seen to express high
levels of the IGF-1R (1). Intermediate cells display an intermediate level of IGF-1R
expression (2). Fully polarised cells with nuclei aligned "on" the basal cytoplasm express
low levels of the IGF-1R (3). Interestingly, these patterns tend to appear in discrete
repeating groups of cells suggesting that this pattern of cell morphology (and IGF-1R
expression) is cyclical and therefore related to the cell cycle. Cells in gland A show a
morphology suggestive of epithelial mesenchymal transformation. Cells with a partially
epithelial / partially mesenchymal morphology that maintain more organised contact with
the basement membrane or adjacent cells (in a similar manner to epithelial cells with a
"picket fence" pattern) show high levels of IGF-1R immunostaining (4). In contrast, cells
with a more mesenchymal morphology that have lost contact with the basement
membrane, show low levels of IGF-1R immunostaining (5). In gland B, the cells have a
mesenchymal morphology but maintain basement membrane or cell-cell contact and
show high levels of IGF-1R immunostaining. At and beyond the point of frank invasion
(Inv), the cancer cells have lost cell-cell contact and show low levels of IGF-1R
immunostaining (CPD). There is also noted to be cell necrosis (Nec) at this point.
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Figure 3.22 IGF-IR immunostaining : cancers and glandular differentiation, x 100
The above specimens show also show a similar process of primitive glandular
differentiation (G) again with a concomitant reduction in IGF-IR immunoexpression
when cancer cells loose their organised "picket fence" type basement membrane or cell-
cell contacts. In specimen a, a row of moderately differentiated cancer cells (S) showing
"picket fence" morphology with alignment on a basement membrane has formed into a
primitive gland (G). This gland exhibits heaped up cells with a disordered morphology
and loss of alignment 011 the basement membrane and a concomitant reduction in IGF-1 R
immunoexpression. In specimen b, a row of cancer cells has similarly formed a primitive
gland (G). In this case, the cells of the gland display also display a disorderd morphology
and a low level of IGF-1R expression.
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Figure 3.23 IGF-IR immunostaining : variation in morphology and loss of cell adhesion,
x 200
The above slide is from a moderately and poorly differentiated cancer showing a
predominantly high level of IGF-IR expression. As in Figure 3.21, moderately
differentiated cancer cells showing cell-cell / cell-basement membrane alignement in a
"picket fence" pattern and poorly differentiated cancer cells showing cell-cell adhesion
both show high levels of IGF-IR immunoexpression. However, when epithelial type
cancer cells show nuclei aligned on the basal aspect of their cell membranes (D) or when
mesenchymal type cancer cells show a loss of cell-cell adhesion (E), then there is a
concomitant reduction in IGF-IR immunoexpression. As in Figure 3.21, this was a rare
phenomenon and tended to occur in small groups of four or more cells in a repeating
pattern rather than in individual cells. This cyclical pattern in IGF-1 R expression in areas
of EMT suggests that chromatin remodelling is involved in the control of IGF-IR gene
expression. It is also notable from the above slide that cells separating from the cancer,
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losing their cell-cell contacts and lying free with a motile-type morphology can be seen to
immunoexpress low IGF-1R levels. For example, cells labelled "a" in the above
specimen have a mesenchymal morphology with lamellipodia and immunoexpress low
IGF-1R levels. It is also notable from the above slide that these cells are seen to undergo
membrane lysis and nuclear extrusion (b) and cell death (c).
Table 3.5 Summary of tissue immunohistochemistry
Specimen Number Average stain (range)
Normal crypt stem cell 12 4 (3-5)
Normal crypt diff. enterocyte 55 0 (0)
Hyperplastic polyp 7 0 (0)
Aberrant crypt focus 5 4 (3-5)
Tubular adenoma 12 3 (3-5)
Tubulovillous adenoma 11 4 (3-5)
Well differentiated cancer 6 5 (3-5)
Mod. differentiated cancer 7 4 (3-5)
Poorly differentiated cancer 8 2 (0-5)
In summary, the tissue immunohistochemistry results show :
1. in the normal colonic crypt the IGF-1R was expressed at high levels in the basal
crypt stem cell region but not in the mid transit amplifying and upper
differentiated regions;
2. in the aberrant, adenomatous and cancerous crypts the IGF-1R was expressed at
high levels throughout the crypt;
3. in areas of epithelial mesenchymal transformation where epithelial type cancer
cells exhibit a fully polarised phenotype and where mesenchymal type cancer
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cells loose their cell-basement membrane or cell-cell contacts, the IGF-1R is
expressed at low levels.
3.5.7. Immunohistochemistry : primary cultures
In order to establish if IGF-1R expression correlated with tumour cell morphology
in vitro, primary cultures and cell lines were established from human colon cancers. The
primary cancers were assayed for IGF-1R immunoexpression and included : 1 well and 1
moderately differentiated cancer (CWD and CMD - both high IGF-1R expression); 2
poorly differentiated cancers with high IGF-1R expression (CPDH); and 2 poorly
differentiated cancers with low IGF-1R expression (CPDL). Of these, primary cultures
were successful in 4 specimens (CMD, 2XCPDL, 1XCPDH) and cell lines were
established from 2 specimens (CMD and CPDL). Cell line CMD exhibited glandular
differentiation 48 hours post confluence and became resistant to passageing at this stage.
Cell line CPDL in contrast exhibited little differentiation post confluence and was more
readily passaged and grown on soft agar (rather than collagen) after a similar period of
time. Initially therefore, and even with this limited number, it appeared that the level of
IGF-1R expression in the cancer specimen did not correlate directly with cell survival in
vitro either as a primary culture or cell line.
A similar pattern of IGF-1R immunostaining was observed in vitro to in vivo.
That is, IGF-1R expression was high in tumour explants, sub confluent primary cultures,
confluent primary cultures and established cell lines if the primary tumour expressed high
IGF-1R levels (and vice versa)(Figure 3.24). However, the findings of basal nucleus
polarity during EMT and the loss of cell adhesion with reduced IGF-1R expression were
not observed in cultures. However, this was more than likely a simple reflection of the
cancer cells' behaviour in culture conditions.
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Figure 3.24. IGF-IR immunostaining in vitro
Poorly differentiated cancer (CPDH)
explant showing IGF-1 R immunostaining.
x 100
Reagent negative control of CPDH
x 200
Reagent negative control of CPDH cell line
x 100
Poorly differentiated confluent primary
culture / IGF-IR immunostaining.
x 100
CPDH cell line subconfluent
IGF-IR immunostaining. x 200
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3.6 Western blotting
To confirm the specificity of the IGF-1R polyclonal antibody, Western blotting of
normal and tumoural cell lysates were performed. This demonstrated molecular weight
specificity, displaying bands at 225kDal. (a+p subunits) and 135kDal. (a subunit) under
non-reducing conditions for normal and tumoural tissue lysates. Although tumoural tissue
appeared to express more of the IGF-1R peptide when equivalences of tumoural and
normal protein were examined, the practical difficulties of the immunoprecipitation
procedure and the lability of the IGF-1R peptide and the low levels of IGF-1R expression
all made verification of this difficult. Importantly however, there were no |3-subunit
molecular weight variants between normal and colonic tumoural cells as there has been
observed between adult and embryonic cells (Alexandrides TK, 1993) and some cancer
cell lines (Kellere M, 1990) and human epidermoid carcinoma KB cells (Garolfalo RS
1992). To examine the 1GF-1R peptide in the cell culture experiments, the low amount of
tissue and the naturally low levels of expression of the receptor presented practical
difficulties. In order to increase the sensitivity of the assay, the cell cultures and normal
mucosal tissue explants were pulse-chase labelled Met-S35 and immunoprecipitation was
performed as previously. Although this technique demonstrated greater sensitivity and a
higher IGF-1R level in cancer cell lines, there was poorer specificity with low molecular
weight degradation products or carry over.
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Figure 3.27 Western blot of normal mucosa (N) and cancer (C)under non-reducing
conditions showing weak bands at 225kDal.(a+|3) and 135kDal. (a) (arrowed). The
cancer specimen also shows some low molecular weight break down / cross reactivity







Figure 3.28 Pulse-chase labelled tissue and radio-immunoprecipitation. Band at 225kDal








3.7. Summary of thesis results :
Northern blotting
IGF-1R RNA was expressed at high levels in colo-rectal adenomas and cancers in
comparison to matched normal mucosa. However, poorly differentiated cancers with an
invasive morphology expressed lower IGF-1R RNA levels in comparison to other
cancers. The expression profile of the IGF-1R does not appear to correlate with this
study's and previous studys' findings of the expression profiles and mutations of the
trans acting c-myc, WT-1 and p53 genes.
Radioligand binding assays
The radioligand binding assays showed saturable kinetics but the errors inherent
in the process of membrane microsomal preparation precluded an accurate comparison
between normal and tumoural specimens.
Immunohistochemistry
In human tissue, the basal stem cell region of normal colonic crypt showed high
levels of IGF-1R immunostaining. In comparison, the mid transit amplifying and upper
differentiated regions of the normal colonic crypt showed low levels of IGF-1R
immunostaining. Aberrant crypt foci showed high levels of IGF-1R immunostaining
throughout the crypt axis, albeit with a gradient in immunoexpression to a limited degree.
Adenomatous and cancerous crypts (well, moderately and non-invasive poorly
differentiated cancers) showed uniformaly high levels of IGF-1R immunostaining.
However, poorly differentiated cancers with an invasive morphology and the invasive
foci of well and moderately differentiated cancers showed low levels of IGF-1R
immunostaining. Low levels of IGF-1R immunostaining were found to correlate with
basal nucleus polarity in epithelial type cancer cells and with loss of cell-cell and cell-
basement membrane adhesion in mesenchymal type cancer cells. These morphological
features were suggestive of the process of epithelial mesenchymal transformation.
Additionally, a cyclical pattern in IGF-1R expression was observed in these foci of cells
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which suggests that chromatin remodelling is involved in the control of IGF-1R gene
expression.
Primary cultures and cell lines
Tumour explants, primary cultures and cell lines all showed IGF-1R
immunostaining. However, it was not possible to observe in vitro basal nucleus polarity
or the loss of cell-cell adhesions with the concomitant reduction in 1GF-1R expression.
Western blotting
Western blotting showed specificity of the anti-IGF-lR polyclonal for the IGF-1R





4.1. Aims and findings
The primary aim of the thesis was to examine the expression profile of the
Insulin-like growth factor type 1 receptor in the colo-rectal polyp-cancer sequence to
determine when changes in IGF-1R expression occur during tumour initiation or
progression. If a change in IGF-1R expression was seen to occur, then a secondary aim
was to determine if this correlated with that of its recognised trans regulators (WT-1, c-
Myc, p53) or some other process.
The results heretofore show for the first time that colo-rectal tumours express high
levels of the IGF-1R de novo at tumour initiation and not during tumour progression.
Additionally (and also consequent to the first statement), high IGF-1R expression was not
found to correlate with changes in its trans regulators c-myc and WT-1 (or, by inference,
p53) during tumour progression. Instead, the study's findings implicate an abnormality of
the stem cell differentiation programme during neoplastic initiation in the aberrant crypt
focus. This high level of IGF-1R immunoexpression continues with neoplastic
progression in adenomas and cancers. Only in advanced invasive cancers was the IGF-1R
immunoexpressed at comparatively lower levels. This was found to correlate with two
specific cell morphologies in foci that appeared to show EMT and invasion : 1. basal
nucleus polarity in epithelial type cancer cells in areas of EMT; 2. loss of cell-cell and
cell-basement membrane adhesion in mesenchymal type cancer cells following EMT.
Finally, and as we will see, the cyclical pattern of IGF-1R expression in invasive foci
suggests that control of expression of the IGF-1R gene in the cancer cell involves
chromatin remodelling.
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4.2. Controls, validation and significances
4.2.a. Northern blotting
The results of each arm of the study were carefully validated at each stage. In the
Northern assays, there was little range in the observed normalised densitometry readings
for normal mucosal IGF-1R using total RNA blots. This was despite the low copy
number and the high molecular weight of the IGF-1R transcript requiring optimisation of
the gel running and transfer. Tumoural specimens exhibited significantly higher
densitometry readings for the IGF-1R total RNA blots (p<0.05). However, the tumoural
specimens exhibited a wider range in that some poorly differentiated cancers had
comparatively lower IGF-1R transcripts. This may well account for the low PCR signal
observed in some cancers in the preliminary study.
4.2.b. Immunohistochemistry
The immunohistochemistry studies employed tissue positive and negative controls
(kidney and liver respectively) along with peptide absorbed reagent negative controls to
validate the sensitivity and specificity of each assay. The mixed cytoplasmic and
membranous staining observed is similar to that of other growth factor receptors. Much
of the receptor exists in the cytoplasmic pool representing post-translational processing of
the pre-peptide, turnover of nonactivated membrane-bound receptors or internalisation of
the activated membrane-bound receptors. The observed staining intensity showed little
variation between histologically similar cells. Importantly, the IGF-1R histo-staining in
stem and tumoural cells was significantly higher than that of normal mucosal transit
amplifying and terminally differentiated epithelial cells (p<0.05). Overall therefore,
normal mucosa immunoexpressed lower IGF-1R levels than tumoural mucosa and this
was in agreement with the Northern assays (in terms of the fraction of IGF-1R transcripts
/ total RNA). Tumours immunoexpressed high IGF-1R levels except in invasive cancers
and again, this was in agreement with the Northern assays. Additionally, normal mucosa
adjacent to tumoural specimens was used as an "internal" positive or negative
immunostaining control (depending on the level of the crypt).
The specificity of the anti-IGF-lR antibody was confirmed by peptide-absorbed
(reagent negative) controls and by Western blotting. Peptide-absorbed controls showed
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an absence of IGF-1R immunostaining for all specimen types. Western blotting of normal
mucosa showed specificity for the a and (3 subunits although some cancer specimens also
showed some lower molecular weight products. This may be a result of necrosis within
the cancer specimen as well as breakdown of the mature IGF-1R peptide during
processing. Certainly, pulse-chase labelling of cell cultures with anti-IGF-lR
immunoprecipitation of the lysate showed low molecular weight breakdown products on
the Western blot.
4,3. Previous studies and the advances of the current study
The study's findings are in agreement with but are a significant advance over
previous studies in this field. Each novel finding in different parts of the polyp-cancer
sequence will be discussed in turn:
4.3.a. Normal versus tumoural tissue : gene expression
The only prior study at variance with the finding of IGF-1R over expression in
colorectal tumours was that of Zenilman and Graham (Zenilman, M.E., 1997). That study
employed a competitive PCR which showed wide variations for all IGF-1R signals when
comparing normal and tumoural mucosae. In contrast, the PCR reaction employed in the
preliminary study by this author showed a consistently low signal for normal epithelium
but a variable signal for cancer epithelium which, with hindsight, may have been due to
the low IGF-1R transcripts in some poorly differentiated cancers. The studies of Hakam
and Coppola (Hakam, A., 1999), Freier and Raz (Freier, S., 1998) and Weber and
Baretton (Weber, M., 2002) have shown by means of immunocytochemistry, RNAse
protection assay and RT-PCR respectively that the IGF-1R is over expressed in colo¬
rectal polyps and cancers in comparison to normal mucosa. High levels of IGF-1R
expression in tumoural as opposed to normal tissues have been noted in numerous other
studies examining other cancer phenotypes (Reviewed Macaulay, V.M., 1992), (Zhang,
L., 1997) and the results of the current study are in agreement with these.
There is now a wealth of data to show that, as a general principle, the growth
factor receptor tyrosine kinase families - including ErbB / HER (Roskoski, 2004),
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PDGFR / KIT (Fletcher, 2004), Met (Corso, 2005), TGF-pR / Wnt (Mishra, 2005) and
VEGFR (Hicklin, 2005) as well as the IGF-1R - are highly expressed in diverse cancer
phenotypes in comparison to their normal tissues of origin. However, as stated, the timing
of and the reasons for these changes in IGF-1R expression in the context of normal
programmed differentiation and the neoplastc initiation and progression have not been
explored.
4.3.b. The normal colo-rectal crypt: immunohistochemistry
The study's initial finding of high levels of IGF-1R immunoexpression in the
basal crypt stem cell compartment of the normal colo-rectal crypt has not been previously
documented. High levels of IGF-1R expression have been documented in all embryonic
tissues (embryonic stem cells) and low levels of IGF-1R expression have been
documented in the majority of postnatal differentiated tissues (Werner H, 1989),
(Chernausek, S.D., 1987). IGF-1R expression during adult stem cell maturation has not
been documented because of the inherent difficulty in identifying the stem cell
compartment and the stem cell maturation process in most adult tissues. In the colo-
rectum where stem cells and stem cell maturation are each compartmentalised in the
crypt (reviewed Potten,1990), the expression profile of IGF-1R during stem cell
maturation can be examined. IGF-1R expression in the normal colonic crypt has
previously only been examined indirectly by means of radioligand binding of IGF-I and -
II in rat epithelium (Laburthe, 1988). That study showed an increased concentration of
ligand binding at the base of the crypt but the study used autoradiographs and was not
able to discern IGF-1R expression according to the cell phenotype. The expression of
other growth factor receptors has been documented to a limited degree in the normal
colonic crypt using similar methodologies - fibroblast growth factor receptor-3 (Vidrich,
2004) and epidermal growth factor receptor (Menard, 1991). Again, these studies have
either examined expression in embryo or in mice using radioligand binding and have not
been able to discern cell phenotypes. Therefore, studies examining IGF-1R expression in
relation to the cell phenotype in the normal adult colon have to date been lacking.
The reduction in IGF-1R immunoexpression specifically at the stage of basal
crypt stem cells migrating into the mid crypt transit amplifying region is an interesting
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finding. The proliferating transit amplifying cells in the mid crypt have a relatively
undifferentiated and partially polarised morphology and immunoexpress low IGF-1R
levels. The proliferating basal crypt stem cells also have an undifferentiated and partially
polarised morphology but immunoexpress high IGF-1R levels. IGF-1R expression does
not therefore appear to correlate in a simple manner with the proliferative behaviour of
cells in the normal colonic crypt. This pattern of IGF-1R expression is in line with that of
several other genes. For example (and as discussed in the introduction), the cell survival
genes bcl-2 and survivin are expressed in the basal crypt region (Merritt, 1995),(Zhang,
2001) (Sinicrope, F.A., 1995). In contrast, proliferative genes such as such as myc, fos,
cyclin D1 and EGFR are expressed in both the basal and mid crypt regions (Chin, L.,
1995), (Stopera, S.A., 1992), (Chailler, P. & Menard, D., 1998). Anti-proliferative or
differentiative genes such as APC and TGF(3RII are expressed in the upper differentiated
compartment (Smith, K.J., 1993) whereas other genes such as E-cadherin are
constitutively expressed throughout the length of the crypt (Sellin, 2001). Although very
limited inferences can be made regarding gene function in this way, it does nevertheless
appear that IGF-1R expression in the basal crypt is a property of the stem cell and its
behaviours - cell survival, cell adhesion, cell dedifferentiation - and not just a reflection
of the proliferative activity of the cells. In line with this, it was also noted that
hyperplastic polyps showed a similar pattern of basal crypt IGF-1R expression to normal
crypts rather than expression throughout the crypt as was noted in the ACF.
There are also interesting parallels between the current study and cell line models.
For example, MacDonald and Bean (MacDonald, R.S., 1993) have shown that the IGF-
1R is expressed in increasing concentrations at the crypt base in a cancer cell line model
of the colonic crypt. Similarly, induced differentiation in colon cancer cell lines results in
reduced expression of the IGF-1R and also in the loss of tumourigenicity (Garrouste, F.,
1997), (Remacle-Bonnet, M.M., 1992), (Augernon, C. et al (1984), (Zarilli, R„ 1996). All
these studies however have used cancer cell lines which are significantly different from
nontransformed adult stem cells. Indeed, and unlike transformed cells, normal colon
epithelial cells are highly growth factor-, anchorage- and cell contact-dependent and
resistant to culture. Whether this reflects the loss of control of IGF-1R expression during
programmed differentiation in the transformed cell is unclear.
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4.3.c. The aberrant crypt focus / tumour initiation
The stem cell origins of neoplasia have previously been argued (Tomlinson,
I.P.M, 1995). However, these arguments are theoretical mathematical ones and are based
upon stem cells being able to proliferate beyond a critical number and avoid terminal
differentiation so that neoplastic transformation can persist (Loeffler, M., 1991).
Evidence for the stem cell origins of neoplasia has been lacking and indeed a "top-down"
aetiology has been argued by some (Shih, I.M., 2001). However, in this study, the
observed pattern of IGF-1R immunoexpression in the ACF with a residual gradient in
immunoexpression representing an expansion of the zone of proliferation, although not
conclusive proof, is highly suggestive of the stem cell origins of neoplasia.
How IGF-1R expression might become uncoupled from the stem cell
differentiation programme in the ACF is unclear. Indeed, the molecular mechanisms
regulating normal stem cell cycling and their commitment to differentiation are poorly
understood (Reviewed- Clatworthy, J.R, 2001). Like the IGF-1R, the bcl-2 and fos genes
are also highly expressed in colonic crypt stem cells, ACFs and cancers (Merritt, A.J. et
al. (1995), (Stopera SA, 1992). Both the bcl-2 and fos genes can be trans activated by the
IGF-1R via their CREB motifs (Pugazhenthi, S., 1999), (Li, X.S., 1994). It is unclear if
this alone accounts for the high expression of bcl-2 and fos in stem and tumour cells. This
is perhaps an over simplification given the complex and highly regulated nature of their
promoters. For example, like the IGF-1R, the bcl-2 and fos promoters have multiple cis-
elements for AP-2, Spl, p53 and WT-1 (Wu, Y., 2001),(Miyashita, T., 1994), (Hewitt,
S.M., 1995). It is equally difficult to discern how these promoters can be specifically
controlled by such ubiquitous trans regulators. Indeed, although Spl is ubiquitously
expressed in embryonic stem cells (Saffer, J., 1991), its expression is associated with
trans activation of the IGF-II ligand rather than the IGF-1R in ras- and polyoma middle
T-transfected Caco-2 cell line models (Cadoret, A., 1998). More specific transcription of
the bcl-2 and fos genes can be directed by oestrogen receptors which appear to act as co-
factors at Spl sites in breast cancer cell lines (Dong, L., 1999), (Duan, R., 1999).
Whether such combinatorial controls exist at the multiple Spl sites in the 5'-flanking and
5'-UTR regions which confer a high basal activity upon the IGF-1R promoter is
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unknown. This is possible given that Spl-IGF-IR promoter interaction is already
targeted and inhibited by p53 and BRCA1 (Ohlsson, C., 1998), (Maor, S.B.,2000) and
given the responsiveness of the IGF-1R gene to hormones such as oestrogen ( Stewart,
A.J., 1990), FSH and GH (Hernandez, E.R., 1991),(Isaksson, O.G.P., 1991) and growth
factors such as PDGF and FGF (Clemmons, K.R., 1980).
The WT-1-, myc- and p53-response regions in the IGF-1R promoter 5'-UTR
(Chambery, D., 1999) (Werner, H., 1994), (Ohlsson, C., 1998) have been cited as
potential mechanisms to explain tumoural IGF-1R expression. However, this study has
contradicted this attractive hypothesis, placing IGF-1R over expression as an event of
tumour initiation, predating any expressive changes in these trans-activators or
repressors. Interestingly, IGF-1R levels have in fact been found to be lower in some
colon cancer cell lines with APC, (3-catenin, E-cadherin and p53 mutations (Playford,
M.P., 2000). Although the reasons for this are unknown, it does suggest that regulators
other than p53 and myc (a transcriptional target of |3-catenin/Tcf) predominate in the
IGF-1R transcript control of cancers (Chambery, D., 1999), (Travali, S., 1991), (Werner,
H., 1996).
What then are the possible causes of IGF-1R expression in transformed colon
crypt cells? Transformed enterocytes in the upper crypt (crypt down morphogenesis) may
reacquire stem cell-like expression patterns of genes such as the IGF-1R, bcl-2 and c-fos
(Stopera, S.A.,1992),(Sinicrope, F.A., 1995) ,(Shpitz, B., 1999) through mutation of
hitherto unrecognised trans-activators or repressors. Alternatively, and in keeping with a
stem cell origin to neoplastic initiation, the expression of these candidate genes at stem
cell levels in the ACF may reflect a more fundamental abnormality of the stem cell's
programmed differentiation occurring at neoplastic initiation. Certainly, identifying how
the promoters of genes such as the IGF-1R are controlled could yield insights into the
process of tumour initiation.
4.3.d. The ACF-polyp-cancer sequence / tumour progression
Adenomatous and most cancerous crypts showed uniform IGF-1R
immunostaining both within and between specimens. The loss of a gradient of IGF-1R
immunoexpression (present in the normal crypt and to a lesser degree in the ACF)
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suggests that a further change occurs in the control of the IGF-1R promoter after the ACF
stage of neoplasia. As noted above, the absence of any variation in the high levels of IGF-
1R immunoexpression noted in all polyps and most cancers or the absence of any
correlation with c-myc or WT-1 expression, again suggests that the IGF-1R is
constitutively expressed de novo in tumours as a result of an abnormality in stem cell
programmed differentiation.
Experimental models testify to the cell's survival dependency on the IGF-1R
being most acute during cell stress / anchorage independence and during cell
transformation (Valentinis, B., 1999), (Resnicoff, M., 1995). The present study also
showed this association in human cancers. That is, lower levels of IGF-1R expression in
some poorly differentiated colon cancers correlated with higher levels of cell death.
However, these cells had also lost their cell-cell and cell-basement membrane anchorage
and these factors can equally be implicated in cell death.
The sensitivity of cancer cells to IGF-1R down regulation is poorly understood.
As discussed in the introduction, the signalling pathways downstream of the IGF-1R and
other growth factor receptors (GFRs) - Ras/Raf/MAPK, PI3K/Akt/Bcl-2/BAD,
14.3.3/raf/BAD, (3-catenin/APC/Tcf and TGF(3RII/Smad - all undergo expressive or
mutational changes in their signalling components in the majority of human cancers
(Blume-Jensen, P., 2001), (Schlessinger, J., 2000), (Baserga, R., 1999), (Chow, J.C.,
1998), (White, M.F., 1998), (Myers, M.G.,Jnr., 1994) (Kulik, G., 1997),(Furlanetto,
R.W., 1997), (Freed, E., 1994), (Playford, M.P., 2000). There is considerable crosstalk
and redundancy in these pathways so that "multiple hits" are thought to be required
during neoplasia to bypass or reduce the cancer cell's dependency on these normal
growth controls. Why the transformed cell should be peculiarly reliant therefore on IGF-
1R function is unclear but this bourne out by in vitro studies which show that IGF-1R
down regulation causes GO arrest and differentiation in normal cells but apoptosis in
transformed cells (Sell, C., 1994), (D'Ambrosio, C., 1995).
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4.3.e. Poorly differentiated cancers : reduced IGF-1R immunoexpression with basal
nucleus polarity and the loss of cell adhesion in foci showing the morphological
features of EMT.
Cancer cells loose their epithelial-type characteristics as they dedifferentiate
during cancer progression. EMT is the final stage in this process. Mesenchymal cells
whether normal or cancerous have the ability to migrate through ECM to varying
degrees. Revealing the molecular mechanisms involved in this process is therefore of
relevance in understanding the pathogenesis of cancer cell invasion and metastasis. Prior
studies show that EMT and consequently the malignant phenotype, are accompanied by a
decrease in epithelial markers such as E-cadherin and an increase in mesenchymal
markers (reviewed Hay ED, 1995; Thiery JP, 2002). Similarly, when mesenchymal cells
regain epithelial morphology (MET) they reexpress epithelial markers and adopt a non¬
invasive behaviour. Of note, this study shows that reduced IGF-1R immunoexpression in
foci that show the morphological features of EMT, rather than simply reflecting the loss
of an epithelial marker, is specific to two particular cell morphologies or cell behaviours
- epithelial cell polarisation and mesenchymal cell loss of adhesion. When the reverse of
these processes occur (mesenchymal cells regaining cell adhesion and MET in
established metastases) then the IGF-1R is concomitantly re-expressed. Additionally, the
cyclical pattern observed in IGF-1R immunoexpression and cell morphology during these
processes implicates certain mechanisms in the control of the gene's expression (see
below).
The observed reduction in IGF-1R immunoexpression in association with a fully
polarised epithelial phenotype in areas of EMT is a novel finding. Although the temporal
sequence of EMT cannot be followed on histology slides, intermediate cell morphologies
lay between the fully polarised epithelial-type cancer cell and the mesenchymal-type
cancer cell suggesting that these were stages in the sequence of EMT. It is interesting to
note that this process shows similarities to differentiation in the normal colo-rectal crypt
and to experimental models of differentiation (see below). However, in contrast to the
normal crypt, fully polarised epithelial-type cancer cells with reduced IGF-1R
immunoexpression showed evidence of mitosis (mitotic bodies and clustering of same-
cell morphologies suggesting cycling).
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The observed reduction in IGF-1R immunoexpression with the loss of cell-cell
adhesion in mesenchymal-type cancer cells is another novel finding of the study. This
was a consistent finding in foci of EMT. Adjacent mesenchymal cells of similar
morphologies that maintained their cell-cell or cell-basement membrane adhesion
maintained high levels of IGF-1R immunoexpression. Furthermore, these morphologies
alternated in a repeating pattern of four or more cells at invasive foci. Interestingly, these
cell behaviours correspond with those of some in vitro models. As was discussed in the
introduction, subconfluent 3T3-L1 preadipocytes, L6E9 skeletal myoblasts and HT29 or
CaCo-2 colon cancer cells will all normally proliferate and scatter in response to IGF
stimulation (Student, A.K., 1980), (Rosenthal, S.M., 1995), (Andre, F., 1999), (Zarilli, R.,
1996). However at confluence, these cells down regulate their IGF-1R and IGF-II
expression and differentiate (Pommier, G.J., 1992), (Garrouste, F., 1997), (Zarilli, R.,
1996). This post confluent differentiation is associated with a permanent loss in the non¬
cancerous cell lines of the ability to re-express the IGF-1R or re-enter the cell cycle.
However, the cancerous cell lines - HT29 and CaCo-2 - are often able to re-express the
IGF-1R after undergoing several rounds of mitosis or repassaging, although they lose
their ability to survive as inoculates in vivo during this period (Augernon, C., 1984). This
result has been reproduced by transfection with an IGF-1R dominant-negative mutant
(Jiang, Y., 1999). This resulted in differentiation and the loss of tumourigenicity in the
A549 lung carcinoma cell line used. The relevance of these in vitro studies conducted
under differing cellular conditions had been unclear. In the current study however we see
for the first time that IGF-1R expression in invasive human cancers is a dynamic and
modulatable phenomenon that correlates with the loss of cell adhesion during invasion.
In vitro studies have implicated IGF-1R signalling pathways in EMT, cell
adhesion and cell motility. For example, IGF-1R activation can result in its co-
localisation as a tripartite complex - IGF-lR/IRS-l~|3-catenin~E-cadherin - effectively
resulting in the down regulation of membranous E-cadherin and the loss of (3-catenin /
Integrin av|35 interaction (Playford, 2000; Morali, 2001; Brooks, 1997). Given that these
signalling functions are presumably reliant upon IGF-1R expression, their actions are
perhaps counter-intuitive given the findings of the current study and the in vitro studies
described above. However, the findings of these signalling studies are entirely dependent
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on the cellular context or culture conditions and a much more consistent finding from
these studies in terms of cellular function is that over expression of the IGF-1R results in
increased cellular adhesion (Mauro, 2002).
The present study also showed that following invasion and metastasis that 1GF-1R
expression could be reinstated upon regaining cell-cell contact. It would be interesting to
learn if this capability varies between cancers or has any correlation with their metastatic
potential. Metastases could however express low IGF-1R levels, albeit with high levels of
necrosis. Although the immunohistochemistry was unable to discern what effect the loss
of cell-cell contact had upon IGF-1R expression in a cancer cell already expressing lower
levels of the receptor, it may be that a threshold level of IGF-1R expression is important
in this regard. This has been shown to be the case in fibroblast transfection studies
(Rubini, M., 1997) and the evidence to date has shown that cancer cells are even more so
dependent upon a level of IGF-1R expression for their survival (Valentinis, B., 1999),
(Sell, C„ 1994), (D'Ambrosio, C., 1995).
4.4. A putative mechanism of IGF-1R transcript control based upon the study's
findings.
The observed cyclical pattern of alternating high and low levels of IGF-1R
immunoexpression with concomitant changes in cell morphology in foci of EMT and
invasion is highly suggestive of regulation of IGF-1R gene expression by chromatin
remodelling. This would explain why cancer cells at these foci would have to undergo
several rounds of clonal expansion (and thus appear in groups of four or more) before
chromatin remodelling 'opened' the IGF-1R promoter to regulation. Epigenetic
regulation of transcription is increasingly recognised as an important factor in
determining stem cell and cancer cell behaviours. This will be an important area for
future research on the IGF-1R.
4.5. A model for the somatic evolution of cancers
Cancer evolution is described in terms of an accumulation throughout disease
progression of mutations in multiple pathways to result in abnormalities of the cell cycle,
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cell survival and differentiation. How these functions can all go awry at tumour initiation
in the aberrant crypt is poorly understood. The present study suggests that some of the
gene expression changes in the aberrant crypt might be traced back "upstream" to
receptor tyrosine kinases such as the IGF-1R. Yet this is only a small part of the story.
Loss of regulatory control in the transformed cell will be dependent upon a host of
additional factors- ligand availability, the concomitant activation of other receptor
tyrosine kinases and the availability of signalling substrates and their downsteam
signalling pathways including ras/raf/MAPK, PI3K/Akt, raf/BAD and (3-catenin/Tcf. All
these are frequent targets during tumour initiation and progression. With regard to the
IGF-1R however, I propose that the findings of this thesis can be encompassed in a
simple model of gene expression. Here we see that the expression of genes such as the
IGF-1R in the newly initiated cancer cell is a legacy of their stem cell origins.
Programmed differentiation of the stem cell involves a coordinated reduction in IGF-1R
expression which is somehow disrupted at tumour initiation. Additional mutations in the
downstream signalling pathways of genes such as the IGF-1R are clonally selected which
further divorce the components of these signalling pathways from control during tumour
progression. In late stage cancers, mesenchymal transformation involves a
'dedifferentiation programme' with a sequence of gene expression changes - such as a
loss IGF-1R expression - which together confer the properties of the malignant
phenotype - such as loss of cell adhesion. These gene expressions can occur in a cyclical
manner suggesting that a basic abnormality in chromatin remodelling for candidate genes
such as the 1GF-1R occurs during neoplasia. Understanding how such candidate genes
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